BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 982] [Article Influence: 188.2] [Reference Citation Analysis]
Number Citing Articles
1 Mossenta M, Busato D, Baboci L, Cintio FD, Toffoli G, Bo MD. New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1086. [PMID: 31370258 DOI: 10.3390/cancers11081086] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
2 Yao Z, Zhang Y, Xu D, Zhou X, Peng P, Pan Z, Xiao N, Yao J, Li Z. Research Progress on Long Non-Coding RNA and Radiotherapy. Med Sci Monit 2019;25:5757-70. [PMID: 31375656 DOI: 10.12659/MSM.915647] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
3 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. Int J Mol Sci. 2020;21. [PMID: 32357520 DOI: 10.3390/ijms21093057] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
5 Wu C, Lin J, Weng Y, Zeng DN, Xu J, Luo S, Xu L, Liu M, Hua Q, Liu CQ, Li JQ, Liao J, Sun C, Zhou J, Chen MS, Liu C, Guo Z, Zhuang SM, Huang JH, Zheng L. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest 2020;130:4679-93. [PMID: 32497024 DOI: 10.1172/JCI135048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
6 Chu Q, Gu X, Zheng Q, Guo Z, Shan D, Wang J, Zhu H. Long noncoding RNA SNHG4: a novel target in human diseases. Cancer Cell Int 2021;21:583. [PMID: 34717631 DOI: 10.1186/s12935-021-02292-1] [Reference Citation Analysis]
7 Xiao X, Mo H, Tu K. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression. Int Immunopharmacol 2020;89:107043. [PMID: 33039961 DOI: 10.1016/j.intimp.2020.107043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen J, Wang D, Wang LH, Liu W, Chiu A, Shariati K, Liu Q, Wang X, Zhong Z, Webb J, Schwartz RE, Bouklas N, Ma M. An Adhesive Hydrogel with "Load-Sharing" Effect as Tissue Bandages for Drug and Cell Delivery. Adv Mater 2020;32:e2001628. [PMID: 32945035 DOI: 10.1002/adma.202001628] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 17.0] [Reference Citation Analysis]
9 Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma: An Aggressive Subtype of Hepatocellular Carcinoma. American Journal of Surgical Pathology 2019;43:943-8. [DOI: 10.1097/pas.0000000000001289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]
10 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Xiao JX, Xu W, Fei X, Hao F, Wang N, Chen Y, Wang J. Anillin facilitates cell proliferation and induces tumor growth of hepatocellular carcinoma via miR-138/SOX4 axis regulation. Transl Oncol 2020;13:100815. [PMID: 32645689 DOI: 10.1016/j.tranon.2020.100815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fang QL, Zhou JY, Xiong Y, Xie CR, Wang FQ, Li YT, Yin ZY, Luo GH. Long non-coding RNA RP11-284P20.2 promotes cell proliferation and invasion in hepatocellular carcinoma by recruiting EIF3b to induce c-met protein synthesis. Biosci Rep 2020;40:BSR20200297. [PMID: 32100822 DOI: 10.1042/BSR20200297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol. 2019;19:167. [PMID: 31638892 DOI: 10.1186/s12876-019-1082-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
14 Langhans B, Nischalke HD, Krämer B, Dold L, Lutz P, Mohr R, Vogt A, Toma M, Eis-Hübinger AM, Nattermann J, Strassburg CP, Gonzalez-Carmona MA, Spengler U. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunol Immunother 2019;68:2055-66. [PMID: 31724091 DOI: 10.1007/s00262-019-02427-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
15 Letouzé E, Shinde J, Renault V, Couchy G, Blanc JF, Tubacher E, Bayard Q, Bacq D, Meyer V, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Zucman-Rossi J. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat Commun 2017;8:1315. [PMID: 29101368 DOI: 10.1038/s41467-017-01358-x] [Cited by in Crossref: 123] [Cited by in F6Publishing: 103] [Article Influence: 30.8] [Reference Citation Analysis]
16 Ziol M, Poté N, Amaddeo G, Laurent A, Nault J, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-rossi J, Barget N, Seror O, Ganne-carrié N, Paradis V, Calderaro J. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology 2018;68:103-12. [DOI: 10.1002/hep.29762] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 18.7] [Reference Citation Analysis]
17 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 241.0] [Reference Citation Analysis]
18 Li Z, Li H, Deng D, Liu R, Lv Y. Mass Spectrometric Assay of Alpha-Fetoprotein Isoforms for Accurate Serological Evaluation. Anal Chem 2020;92:4807-13. [DOI: 10.1021/acs.analchem.9b03995] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
19 Xiong L, Wu F, Wu Q, Xu L, Cheung OK, Kang W, Mok MT, Szeto LLM, Lun CY, Lung RW, Zhang J, Yu KH, Lee SD, Huang G, Wang CM, Liu J, Yu Z, Yu DY, Chou JL, Huang WH, Feng B, Cheung YS, Lai PB, Tan P, Wong N, Chan MW, Huang TH, Yip KY, Cheng AS, To KF. Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. Nat Commun 2019;10:335. [PMID: 30659195 DOI: 10.1038/s41467-018-08245-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 17.0] [Reference Citation Analysis]
20 Lian Y, Fan W, Huang Y, Wang H, Wang J, Zhou L, Wu X, Deng M, Huang Y. Downregulated Trophinin-Associated Protein Plays a Critical Role in Human Hepatocellular Carcinoma Through Upregulation of Tumor Cell Growth and Migration. Oncol Res 2018;26:691-701. [PMID: 29117881 DOI: 10.3727/096504017X15101398724809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
21 Krupenko NI, Sharma J, Fogle HM, Pediaditakis P, Strickland KC, Du X, Helke KL, Sumner S, Krupenko SA. Knockout of Putative Tumor Suppressor Aldh1l1 in Mice Reprograms Metabolism to Accelerate Growth of Tumors in a Diethylnitrosamine (DEN) Model of Liver Carcinogenesis. Cancers (Basel) 2021;13:3219. [PMID: 34203215 DOI: 10.3390/cancers13133219] [Reference Citation Analysis]
22 Cho Y, Park MJ, Kim K, Park JY, Kim J, Kim W, Yoon JH. Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E472. [PMID: 31940813 DOI: 10.3390/ijms21020472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Williams M, Liu X, Zhang Y, Reske J, Bahal D, Gohl TG, Hollern D, Ensink E, Kiupel M, Luo R, Das R, Xiao H. NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21WAF1/CIP1 overexpression, which is reversed by metformin. Oncogene 2020;39:3821-36. [PMID: 32203160 DOI: 10.1038/s41388-020-1256-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wu Y, Li X, Chen M, Liu Z, Zhang X, Zheng S, Xu X. Phosphorylation of PED/PEA-15 at Ser116 and phosphorylation of p27 at Thr187 indicates a poor prognosis in hepatocellular carcinoma. Oncol Lett 2021;21:177. [PMID: 33574916 DOI: 10.3892/ol.2021.12438] [Reference Citation Analysis]
25 Faranda T, Grossi I, Manganelli M, Marchina E, Baiocchi G, Portolani N, Crosatti M, De Petro G, Salvi A. Differential expression profiling of long non-coding RNA GAS5 and miR-126-3p in human cancer cells in response to sorafenib. Sci Rep 2019;9:9118. [PMID: 31235746 DOI: 10.1038/s41598-019-45604-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
26 Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R, Ma H, Kang T. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett 2019;442:252-61. [PMID: 30423408 DOI: 10.1016/j.canlet.2018.11.006] [Cited by in Crossref: 92] [Cited by in F6Publishing: 97] [Article Influence: 30.7] [Reference Citation Analysis]
27 Liang Y, Feng Y, Zong M, Wei XF, Lee J, Feng Y, Li H, Yang GS, Wu ZJ, Fu XD, Feng GS. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET. Hepatology 2018;67:1807-22. [PMID: 29152756 DOI: 10.1002/hep.29661] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
28 Liu YF, Sun XY, Zhang JK, Wang ZH, Ren ZG, Li J, Guo WZ, Zhang SJ. hMex-3A is associated with poor prognosis and contributes to the progression of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:147-53. [PMID: 32291179 DOI: 10.1016/j.hbpd.2020.03.005] [Reference Citation Analysis]
29 Sun T, Kang Y, Liu J, Zhang Y, Ou L, Liu X, Lai R, Shao L. Nanomaterials and hepatic disease: toxicokinetics, disease types, intrinsic mechanisms, liver susceptibility, and influencing factors. J Nanobiotechnology 2021;19:108. [PMID: 33863340 DOI: 10.1186/s12951-021-00843-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Pan Y, Mei J, Chen J, Zhang D, Wang J, Wang X, Yi M, Zhou Z, Zhang Y, Chen M, Guo R, Xu L. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma. Ann Surg Oncol 2021. [PMID: 34637058 DOI: 10.1245/s10434-021-10903-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chen P, Luo X, Dai G, Jiang Y, Luo Y, Peng S, Wang H, Xie P, Qu C, Lin W, Hong J, Ning X, Li A. Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. Exp Mol Med 2020;52:1062-74. [PMID: 32632241 DOI: 10.1038/s12276-020-0461-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
32 Xu Q, Xu H, Deng R, Li N, Mu R, Qi Z, Shen Y, Wang Z, Wen J, Zhao J, Weng D, Huang W. Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy. Front Cell Dev Biol 2021;9:669145. [PMID: 34422799 DOI: 10.3389/fcell.2021.669145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Shao XY, Dong J, Zhang H, Wu YS, Zheng L. Systematic Analyses of the Role of the Reader Protein of N 6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma. Front Mol Biosci 2020;7:577460. [PMID: 33344502 DOI: 10.3389/fmolb.2020.577460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Vermersch M, Mulé S, Chalaye J, Galletto Pregliasco A, Emsen B, Amaddeo G, Monnet A, Stemmer A, Baranes L, Laurent A, Leroy V, Itti E, Luciani A. Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients. J Clin Med 2021;10:4017. [PMID: 34501465 DOI: 10.3390/jcm10174017] [Reference Citation Analysis]
35 Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu Z, Li Q, Luo M, Liang R, Ye J. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:447. [PMID: 31684985 DOI: 10.1186/s13046-019-1412-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
36 Song S, Shi Y, Wu W, Wu H, Chang L, Peng P, Zhang L, Fan J, Gu J, Ruan Y. Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus. Gut 2020:gutjnl-2020-321386. [PMID: 33303565 DOI: 10.1136/gutjnl-2020-321386] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Brown ZJ, Heinrich B, Greten TF. Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. Methods Protoc 2018;1:E21. [PMID: 31164564 DOI: 10.3390/mps1020021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 He S, Yang J, Jiang S, Li Y, Han X. Circular RNA circ_0000517 regulates hepatocellular carcinoma development via miR-326/IGF1R axis. Cancer Cell Int 2020;20:404. [PMID: 32863763 DOI: 10.1186/s12935-020-01496-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
39 Yin L, Zhou L, Xu R. Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis. Front Mol Biosci 2020;7:599142. [PMID: 33681288 DOI: 10.3389/fmolb.2020.599142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Yu L, Wang F, Tai M, Li J, Gong S, Zhou Z, Yin X, Gu X, Li C. 6H2L, a novel synthetic derivative of bifendate, induces apoptosis in hepatoma cells via mitochondrial and MAPK pathway. Eur J Pharmacol 2020;882:173299. [PMID: 32589884 DOI: 10.1016/j.ejphar.2020.173299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Meng L, Zhou Y, Ju S, Han J, Song C, Kong J, Wu Y, Lu S, Xu J, Yuan W, Zhang E, Wang C, Hu Z, Gu Y, Luo R, Wang X. A cis-eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma. Cancer Med 2019;8:6476-84. [PMID: 31489978 DOI: 10.1002/cam4.2487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Shimada S, Mogushi K, Akiyama Y, Furuyama T, Watanabe S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Tanabe M, Wands JR, Tanaka S. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine. 2019;40:457-470. [PMID: 30598371 DOI: 10.1016/j.ebiom.2018.12.058] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 20.7] [Reference Citation Analysis]
43 Li H, Lan T, Xu L, Liu H, Wang J, Li J, Chen X, Huang J, Li X, Yuan K, Zeng Y, Wu H. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner. J Exp Clin Cancer Res 2020;39:128. [PMID: 32631394 DOI: 10.1186/s13046-020-01638-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
44 Shen S, Yan J, Zhang Y, Dong Z, Xing J, He Y. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma. Ann Transl Med 2021;9:59. [PMID: 33553352 DOI: 10.21037/atm-20-7396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Li L, Wang T, Li S, Chen Z, Wu J, Cao W, Wo Q, Qin X, Xu J. TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway. Front Oncol 2020;10:562823. [PMID: 33542896 DOI: 10.3389/fonc.2020.562823] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
46 Cho Y, Han J, Kim W. Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma. J Liver Cancer 2019;19:1-11. [DOI: 10.17998/jlc.19.1.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Jordan AC, Wu J. Immunotherapy in hepatocellular carcinoma: Combination strategies. World J Meta-Anal 2020; 8(3): 190-209 [DOI: 10.13105/wjma.v8.i3.190] [Reference Citation Analysis]
48 Silva L, Egea J, Villanueva L, Ruiz M, Llopiz D, Repáraz D, Aparicio B, Lasarte-Cia A, Lasarte JJ, Ruiz de Galarreta M, Lujambio A, Sangro B, Sarobe P. Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses Against Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3397. [PMID: 33207844 DOI: 10.3390/cancers12113397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Liang Y, Wang H, Yu H, Feng G, Liu F, Ma M, Zhang Y, Gu N. Magnetic navigation helps PLGA drug loaded magnetic microspheres achieve precise chemoembolization and hyperthermia. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2020;588:124364. [DOI: 10.1016/j.colsurfa.2019.124364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
50 Jiao Y, Li Y, Jia B, Chen Q, Pan G, Hua F, Liu Y. The prognostic value of lncRNA SNHG4 and its potential mechanism in liver cancer. Biosci Rep 2020;40:BSR20190729. [PMID: 31967298 DOI: 10.1042/BSR20190729] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
51 Liu B, Tian Y, Chen M, Shen H, Xia J, Nan J, Yan T, Wang Y, Shi L, Shen B, Yu H, Cai X. CircUBAP2 Promotes MMP9-Mediated Oncogenic Effect via Sponging miR-194-3p in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:675043. [PMID: 34239873 DOI: 10.3389/fcell.2021.675043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Gores GJ, Lieberman D. Good News–Bad News: Current Status of GI Cancers. Gastroenterology 2016;151:13-6. [DOI: 10.1053/j.gastro.2016.05.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
53 Zong L, Peng H, Sun C, Li F, Zheng M, Chen Y, Wei H, Sun R, Tian Z. Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice. Nat Commun. 2019;10:221. [PMID: 30644386 DOI: 10.1038/s41467-018-08096-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
54 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
55 Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72:320-341. [PMID: 31954495 DOI: 10.1016/j.jhep.2019.10.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 40.0] [Reference Citation Analysis]
56 Hung MC, Yang R, Sun Y. Powering Tumor Metastasis with Recycled Fuel. Cancer Cell 2016;30:374-5. [PMID: 27622330 DOI: 10.1016/j.ccell.2016.08.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Koenig AB, Barajas JM, Guerrero MJ, Ghoshal K. A Comprehensive Analysis of Argonaute-CLIP Data Identifies Novel, Conserved and Species-Specific Targets of miR-21 in Human Liver and Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E851. [PMID: 29538313 DOI: 10.3390/ijms19030851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
58 Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188382. [PMID: 32522600 DOI: 10.1016/j.bbcan.2020.188382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
59 Fang AP, Long JA, Zhang YJ, Liu ZY, Li QJ, Zhang DM, Luo Y, Zhong RH, Zhou ZG, Xu YJ, Xu XJ, Ling WH, Chen MS, Zhu HL. Serum Bioavailable, Rather Than Total, 25-hydroxyvitamin D Levels Are Associated With Hepatocellular Carcinoma Survival. Hepatology 2020;72:169-82. [PMID: 31677282 DOI: 10.1002/hep.31013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
60 Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, Yamada K, Hori Y, Tabata K, Takase K, Matsui J, Funahashi Y, Nomoto K. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109:3993-4002. [PMID: 30447042 DOI: 10.1111/cas.13806] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 23.3] [Reference Citation Analysis]
61 Zhang W, Han L, Xing P, Liu B, Sun Z, Zhou W, Dong J. LncRNA RHPN1-AS1 accelerates proliferation, migration, and invasion via regulating miR-485-5p/BSG axis in hepatocellular carcinoma. Naunyn-Schmiedeberg's Arch Pharmacol 2020;393:2543-51. [DOI: 10.1007/s00210-020-01889-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
62 Ma H, Yuan L, Li W, Xu K, Yang L. The LncRNA H19/miR-193a-3p axis modifies the radio-resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1. J Cell Biochem 2018;119:8325-35. [PMID: 29968942 DOI: 10.1002/jcb.26883] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
63 Wu MY, Yiang GT, Cheng PW, Chu PY, Li CJ. Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. J Clin Med. 2018;7. [PMID: 30104473 DOI: 10.3390/jcm7080213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
64 Chesnokov MS, Khesina PA, Shavochkina DA, Kustova IF, Dyakov LM, Morozova OV, Mugue NS, Kudashkin NE, Moroz EA, Patyutko YI, Lazarevich NL. Shift in VEGFA isoform balance towards more angiogenic variants is associated with tumor stage and differentiation of human hepatocellular carcinoma. PeerJ 2018;6:e4915. [PMID: 29888133 DOI: 10.7717/peerj.4915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
65 He Z, Tian M, Fu X. Reduced expression of miR-30c-5p promotes hepatocellular carcinoma progression by targeting RAB32. Mol Ther Nucleic Acids 2021;26:603-12. [PMID: 34703646 DOI: 10.1016/j.omtn.2021.08.033] [Reference Citation Analysis]
66 Lozano-Ruiz B, González-Navajas JM. The Emerging Relevance of AIM2 in Liver Disease. Int J Mol Sci 2020;21:E6535. [PMID: 32906750 DOI: 10.3390/ijms21186535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Vishnoi K, Viswakarma N, Rana A, Rana B. Transcription Factors in Cancer Development and Therapy. Cancers (Basel) 2020;12:E2296. [PMID: 32824207 DOI: 10.3390/cancers12082296] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
68 Gao Y, Wang X, Sang Z, Li Z, Liu F, Mao J, Yan D, Zhao Y, Wang H, Li P, Ying X, Zhang X, He K, Wang H. Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues. Sci Rep 2017;7:45913. [PMID: 28378759 DOI: 10.1038/srep45913] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
69 O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 2018; 24(39): 4436-4447 [PMID: 30357021 DOI: 10.3748/wjg.v24.i39.4436] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 45] [Article Influence: 19.0] [Reference Citation Analysis]
70 Cao G, Liu Y, Li L, Zhao X, Liu R, Liu J, Liu J, Cao H. A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating Hepatocellular Carcinoma Patients. Cancer Manag Res 2021;13:5373-82. [PMID: 34262345 DOI: 10.2147/CMAR.S308097] [Reference Citation Analysis]
71 Zhang X, Lin C, Chan W, Liu K, Lu A, Lin G, Hu R, Shi H, Zhang H, Yang Z. Dual-Functional Liposomes with Carbonic Anhydrase IX Antibody and BR2 Peptide Modification Effectively Improve Intracellular Delivery of Cantharidin to Treat Orthotopic Hepatocellular Carcinoma Mice. Molecules 2019;24:E3332. [PMID: 31547459 DOI: 10.3390/molecules24183332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
72 Li W, Wu H, Xu X, Zhang Y. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. Aging (Albany NY) 2021;13:11564-94. [PMID: 33867349 DOI: 10.18632/aging.202853] [Reference Citation Analysis]
73 Xiao Q, Liu H, Wang HS, Cao MT, Meng XJ, Xiang YL, Zhang YQ, Shu F, Zhang QG, Shan H, Jiang GM. Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy. Theranostics 2020;10:10245-61. [PMID: 32929346 DOI: 10.7150/thno.47045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
74 Zhang Z, Tang D, Wang B, Wang Z, Liu M. Analysis of miRNA-mRNA regulatory network revealed key genes induced by aflatoxin B1 exposure in primary human hepatocytes. Mol Genet Genomic Med 2019;7:e971. [PMID: 31502424 DOI: 10.1002/mgg3.971] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
75 Xu W, Wu Y, Fang X, Zhang Y, Cai N, Wen J, Liao J, Zhang B, Chen X, Chu L. SnoRD126 promotes the proliferation of hepatocellular carcinoma cells through transcriptional regulation of FGFR2 activation in combination with hnRNPK. Aging (Albany NY) 2021;13:13300-17. [PMID: 33891563 DOI: 10.18632/aging.203014] [Reference Citation Analysis]
76 Chen DP, Ning WR, Li XF, Wei Y, Lao XM, Wang JC, Wu Y, Zheng L. Peritumoral monocytes induce cancer cell autophagy to facilitate the progression of human hepatocellular carcinoma. Autophagy 2018;14:1335-46. [PMID: 29940792 DOI: 10.1080/15548627.2018.1474994] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
77 Lin Z, Miao D, Xu Q, Wang X, Yu F. A novel focal adhesion related gene signature for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2021;13:10724-48. [PMID: 33850056 DOI: 10.18632/aging.202871] [Reference Citation Analysis]
78 Rodríguez-Hernández MA, González R, de la Rosa ÁJ, Gallego P, Ordóñez R, Navarro-Villarán E, Contreras L, Rodríguez-Arribas M, González-Gallego J, Álamo-Martínez JM, Marín-Gómez LM, Del Campo JA, Quiles JL, Fuentes JM, de la Cruz J, Mauriz JL, Padillo FJ, Muntané J. Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells. J Cell Physiol 2018;234:692-708. [PMID: 30132846 DOI: 10.1002/jcp.26855] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
79 Meng Z, Ren Q, Zhong G, Li S, Chen Y, Wu W, Feng Y, Mao M, Zhang F, Long G. Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α-Fetoprotein. J Mol Diagn 2021;23:1174-84. [PMID: 34182124 DOI: 10.1016/j.jmoldx.2021.06.003] [Reference Citation Analysis]
80 Du Y, Shi X, Ma W, Wen P, Yu P, Wang X, Fang P, Chen A, Gao Z, Cui K. Phthalates promote the invasion of hepatocellular carcinoma cells by enhancing the interaction between Pregnane X receptor and E26 transformation specific sequence 1. Pharmacol Res 2021;169:105648. [PMID: 33965509 DOI: 10.1016/j.phrs.2021.105648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
81 Lin CY, Lin CC, Wang CC, Chen CL, Hu TH, Hung CH, Huang PY, Tsai MC. The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection. World J Surg. 2020;44:247-257. [PMID: 31559485 DOI: 10.1007/s00268-019-05197-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Huang Y, Wang H, Lian Y, Wu X, Zhou L, Wang J, Deng M, Huang Y. Upregulation of kinesin family member 4A enhanced cell proliferation via activation of Akt signaling and predicted a poor prognosis in hepatocellular carcinoma. Cell Death Dis 2018;9:141. [PMID: 29396392 DOI: 10.1038/s41419-017-0114-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
83 Maraolo AE, Buonomo AR, Zappulo E, Scotto R, Pinchera B, Gentile I. Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. RRCT 2019;14:129-35. [DOI: 10.2174/1574887114666181204102516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
85 Gunes A, Bagirsakci E, Iscan E, Cakan-Akdogan G, Aykutlu U, Senturk S, Ozhan G, Erdal E, Nart D, Barbet FY, Atabey N. Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma. Oncotarget 2018;9:36849-66. [PMID: 30627326 DOI: 10.18632/oncotarget.26402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
86 Yu T, Lu S, Xie W. Downregulation of GNA14 in hepatocellular carcinoma indicates an unfavorable prognosis. Oncol Lett 2020;20:165-72. [PMID: 32565944 DOI: 10.3892/ol.2020.11538] [Reference Citation Analysis]
87 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
88 Shen S, Butrin A, Doubleday PF, Melani RD, Beaupre BA, Tavares MT, Ferreira GM, Kelleher NL, Moran GR, Liu D, Silverman RB. Turnover and Inactivation Mechanisms for (S)-3-Amino-4,4-difluorocyclopent-1-enecarboxylic Acid, a Selective Mechanism-Based Inactivator of Human Ornithine Aminotransferase. J Am Chem Soc 2021;143:8689-703. [PMID: 34097381 DOI: 10.1021/jacs.1c02456] [Reference Citation Analysis]
89 Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Yamashita YI, Yoshida N, Chikamoto A, Baba H. The microbiome and hepatobiliary-pancreatic cancers.Cancer Lett. 2017;402:9-15. [PMID: 28527946 DOI: 10.1016/j.canlet.2017.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]
90 Zhu J, Yu H, Chen S, Yang P, Dong Z, Ling Y, Tang H, Bai S, Yang W, Tang L, Shen F, Wang H, Wen W. Prognostic significance of combining high mobility group Box-1 and OV-6 expression in hepatocellular carcinoma. Sci China Life Sci 2018;61:912-23. [PMID: 29441453 DOI: 10.1007/s11427-017-9188-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
91 Kudo M. Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial. Liver Cancer. 2018;7:225-234. [PMID: 30319982 DOI: 10.1159/000492535] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
92 Dou D, Zhang ZY, Wu ZY, Qiu XD, Zhong XG. Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:5497041. [PMID: 32904600 DOI: 10.1155/2020/5497041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
93 Ma B, Chen K, Liu P, Li M, Liu J, Sideras K, Sprengers D, Biermann K, Wang W, IJzermans JNM, Cao W, Kwekkeboom J, Peppelenbosch MP, Pan Q. Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma. J Mol Med (Berl) 2019;97:77-88. [PMID: 30456450 DOI: 10.1007/s00109-018-1717-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
94 Li Y, Chen G, Yan Y, Fan Q. CASC15 promotes epithelial to mesenchymal transition and facilitates malignancy of hepatocellular carcinoma cells by increasing TWIST1 gene expression via miR-33a-5p sponging. European Journal of Pharmacology 2019;860:172589. [DOI: 10.1016/j.ejphar.2019.172589] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
95 Nguyen T, Le A. The Metabolism of Renal Cell Carcinomas and Liver Cancer. In: Le A, editor. The Heterogeneity of Cancer Metabolism. Cham: Springer International Publishing; 2018. pp. 107-18. [DOI: 10.1007/978-3-319-77736-8_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
96 Dong Q, Du Y, Li H, Liu C, Wei Y, Chen MK, Zhao X, Chu YY, Qiu Y, Qin L, Yamaguchi H, Hung MC. EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Res 2019;79:819-29. [PMID: 30573522 DOI: 10.1158/0008-5472.CAN-18-1273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
97 Lee YC, Wang JH, Chen CH, Hung CH, Lo KC, Yen YH, Kee KM, Hu TH, Lu SN, Kuo YH. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study. Kaohsiung J Med Sci 2021. [PMID: 34166565 DOI: 10.1002/kjm2.12413] [Reference Citation Analysis]
98 Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
99 Chen J, Chen C, Lin Y, Su Y, Yu X, Jiang Y, Chen Z, Ke S, Lin S, Chen L, Zhang Z, Zhang T. Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion. FEBS Open Bio 2021;11:1771-84. [PMID: 33989451 DOI: 10.1002/2211-5463.13173] [Reference Citation Analysis]
100 Ge X, Yao Y, Li J, Li Z, Han X. Role of LncRNAs in the Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Front Oncol 2021;11:690800. [PMID: 34113574 DOI: 10.3389/fonc.2021.690800] [Reference Citation Analysis]
101 Teng CF, Wu HC, Su IJ, Jeng LB. Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma. Viruses 2020;12:E945. [PMID: 32859114 DOI: 10.3390/v12090945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
102 Li N, Gao W, Zhang YF, Ho M. Glypicans as Cancer Therapeutic Targets. Trends Cancer 2018;4:741-54. [PMID: 30352677 DOI: 10.1016/j.trecan.2018.09.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 15.0] [Reference Citation Analysis]
103 Li L, Zhang W, Zhao S, Sun M. FOS-like antigen 1 is a prognostic biomarker in hepatocellular carcinoma. Saudi J Gastroenterol 2019;25:369-76. [PMID: 31274473 DOI: 10.4103/sjg.SJG_595_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
104 Dow M, Pyke RM, Tsui BY, Alexandrov LB, Nakagawa H, Taniguchi K, Seki E, Harismendy O, Shalapour S, Karin M, Carter H, Font-Burgada J. Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 2018;115:E9879-88. [PMID: 30287485 DOI: 10.1073/pnas.1811029115] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
105 Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019;28:228-235. [PMID: 30851906 DOI: 10.1016/j.suronc.2019.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
106 Ito T, Ishii T, Sumiyoshi S, Ogiso S, Fukumitsu K, Ito T, Yagi S, Seo S, Hata K, Taura K, Uemoto S. Living donor liver transplantation for combined hepatocellular-cholangiocarcinoma: A case series of four patients. Int J Surg Case Rep 2020;74:46-52. [PMID: 32791447 DOI: 10.1016/j.ijscr.2020.07.069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. Int J Mol Sci 2020;21:E5840. [PMID: 32823989 DOI: 10.3390/ijms21165840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
108 Qiao GL, Chen L, Jiang WH, Yang C, Yang CM, Song LN, Chen Y, Yan HL, Ma LJ. Hsa_circ_0003998 may be used as a new biomarker for the diagnosis and prognosis of hepatocellular carcinoma. Onco Targets Ther 2019;12:5849-60. [PMID: 31410028 DOI: 10.2147/OTT.S210363] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
109 Zhou YF, Song SS, Tian MX, Tang Z, Wang H, Fang Y, Qu WF, Jiang XF, Tao CY, Huang R, Zhou PY, Zhu SG, Zhou J, Fan J, Liu WR, Shi YH. Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis. J Immunother Cancer 2021;9:e003031. [PMID: 34413167 DOI: 10.1136/jitc-2021-003031] [Reference Citation Analysis]
110 Ye Z, Wu W, Qin Y, Hu J, Liu C, Seeberger PH, Yin J. An Integrated Therapeutic Delivery System for Enhanced Treatment of Hepatocellular Carcinoma. Adv Funct Mater 2018;28:1706600. [DOI: 10.1002/adfm.201706600] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
111 Lu Y, Li X, Liu H, Xue J, Zeng Z, Dong X, Zhang T, Wu G, Yang K, Xu S. β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma. Oncogene 2021;40:1269-83. [PMID: 33420362 DOI: 10.1038/s41388-020-01596-2] [Reference Citation Analysis]
112 Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 2020;5:87. [PMID: 32532960 DOI: 10.1038/s41392-020-0187-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 35.0] [Reference Citation Analysis]
113 Yu Z, Guo J, Hu M, Gao Y, Huang L. Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma. ACS Nano 2020;14:4816-28. [PMID: 32188241 DOI: 10.1021/acsnano.0c00708] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 36.0] [Reference Citation Analysis]
114 Zhao Y, Zhang L, Zhang Y, Meng B, Ying W, Qian X. Identification of hedgehog signaling as a potential oncogenic driver in an aggressive subclass of human hepatocellular carcinoma: A reanalysis of the TCGA cohort. Sci China Life Sci 2019;62:1481-91. [PMID: 31313086 DOI: 10.1007/s11427-019-9560-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Yu MM, Feng YH, Zheng L, Zhang J, Luo GH. Short hairpin RNA-mediated knockdown of nuclear factor erythroid 2-like 3 exhibits tumor-suppressing effects in hepatocellular carcinoma cells. World J Gastroenterol 2019; 25(10): 1210-1223 [PMID: 30886504 DOI: 10.3748/wjg.v25.i10.1210] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
116 Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology. 2017;153:812-826. [PMID: 28624577 DOI: 10.1053/j.gastro.2017.06.007] [Cited by in Crossref: 265] [Cited by in F6Publishing: 272] [Article Influence: 66.3] [Reference Citation Analysis]
117 Ang C, Shields A, Xiu J, Gatalica Z, Reddy S, Salem ME, Farhangfar C, Hwang J, Astsaturov I, Marshall JL. Molecular characteristics of hepatocellular carcinomas from different age groups. Oncotarget 2017;8:101591-8. [PMID: 29254188 DOI: 10.18632/oncotarget.21353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
118 Lanton T, Shriki A, Nechemia-Arbely Y, Abramovitch R, Levkovitch O, Adar R, Rosenberg N, Paldor M, Goldenberg D, Sonnenblick A, Peled A, Rose-John S, Galun E, Axelrod JH. Interleukin 6-dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis. Hepatology 2017;65:1600-11. [PMID: 28027584 DOI: 10.1002/hep.29004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
119 Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, Kisiel JB, Reddy KR, Lidgard GP, Johnson SC, Bruinsma JJ. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020;. [PMID: 32889146 DOI: 10.1016/j.cgh.2020.08.065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
120 Pavel M, Sanchez Cabus S, Crespo G, Ferrer J, Fondevila C, Fuster J, Garcia-valdecasas J. Role of Adult Living Donor Liver Transplantation in the Treatment of Hepatocellular Carcinoma Within and Beyond Milan Criteria: A Comparative Study. Transplantation Proceedings 2018;50:1386-95. [DOI: 10.1016/j.transproceed.2018.02.093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
121 Feng GS, Hanley KL, Liang Y, Lin X. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology 2021;73 Suppl 1:104-14. [PMID: 32715491 DOI: 10.1002/hep.31479] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
122 Zhong XP, Zhang YF, Mei J, Li SH, Kan A, Lu LH, Chen MS, Wei W, Guo RP. Anatomical versus Non-anatomical Resection for Hepatocellular Carcinoma with Microscope Vascular Invasion: A Propensity Score Matching Analysis. J Cancer 2019;10:3950-7. [PMID: 31417639 DOI: 10.7150/jca.32592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
123 Zhu W, Cheng L, Li M, Zuo D, Zhang N, Zhuang H, Xie D, Zeng Q, Hutchison JA, Zhao Y. Frequency Shift Raman-Based Sensing of Serum MicroRNAs for Early Diagnosis and Discrimination of Primary Liver Cancers. Anal Chem 2018;90:10144-51. [DOI: 10.1021/acs.analchem.8b01798] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
124 Mo Z, Cao Z, Yu L, Wang Y, Li P, Lin Y, Zhang S. An Integrative Analysis Reveals the Potential Mechanism between Herbal Medicine Yinchen and Immunoregulation in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:8886914. [PMID: 33457419 DOI: 10.1155/2020/8886914] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Kalathil SG, Wang K, Hutson A, Iyer R, Thanavala Y. Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. Oncoimmunology 2020;9:1824863. [PMID: 33101775 DOI: 10.1080/2162402X.2020.1824863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
126 Yamada N, Matsushima-nishiwaki R, Kozawa O. Quercetin suppresses the migration of hepatocellular carcinoma cells stimulated by hepatocyte growth factor or transforming growth factor-α: Attenuation of AKT signaling pathway. Archives of Biochemistry and Biophysics 2020;682:108296. [DOI: 10.1016/j.abb.2020.108296] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
127 Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, Yang X, Wang B. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:7977-87. [PMID: 34605616 DOI: 10.1002/cam4.4312] [Reference Citation Analysis]
128 Roehlen N, Baumert TF. Uncovering the mechanism of action of aspirin in HCC chemoprevention. EBioMedicine 2019;46:21-2. [PMID: 31399384 DOI: 10.1016/j.ebiom.2019.07.047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
129 Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803 [PMID: 31662820 DOI: 10.4251/wjgo.v11.i10.788] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
130 Zheng R, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. Cancer Med 2020;9:4232-50. [PMID: 32281295 DOI: 10.1002/cam4.3045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
131 Chen X, Zhang X, Zhang L, Gao Y, Wang C, Hong W, Zhao G, Li L, Liu R, Wang C. Amphiphilic Janus nanoparticles for imaging-guided synergistic chemo-photothermal hepatocellular carcinoma therapy in the second near-infrared window. Nanoscale 2021;13:3974-82. [PMID: 33595029 DOI: 10.1039/d0nr09017d] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Cui RJ, Fan JL, Lin YC, Pan YJ, Liu C, Wan JH, Wang W, Jiang ZY, Zheng XL, Tang JB, Yu XG. miR-124-3p availability is antagonized by LncRNA-MALAT1 for Slug-induced tumor metastasis in hepatocellular carcinoma. Cancer Med 2019;8:6358-69. [PMID: 31466138 DOI: 10.1002/cam4.2482] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
133 Tang F, Gao R, Jeevan-Raj B, Wyss CB, Kalathur RKR, Piscuoglio S, Ng CKY, Hindupur SK, Nuciforo S, Dazert E, Bock T, Song S, Buechel D, Morini MF, Hergovich A, Matthias P, Lim DS, Terracciano LM, Heim MH, Hall MN, Christofori G. LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function. Nat Commun 2019;10:5755. [PMID: 31848340 DOI: 10.1038/s41467-019-13591-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
134 Yi T, Luo H, Qin F, Jiang Q, He S, Wang T, Su J, Song S, Qin X, Qin Y, Zhou X, Huang Z. LncRNA LL22NC03-N14H11.1 promoted hepatocellular carcinoma progression through activating MAPK pathway to induce mitochondrial fission. Cell Death Dis 2020;11:832. [PMID: 33028809 DOI: 10.1038/s41419-020-2584-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
135 Mishra M, Jayal P, Karande AA, Chandra N. Identification of a co-target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach. FEBS J 2018;285:3977-92. [PMID: 30136368 DOI: 10.1111/febs.14641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
136 Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia M, Li N, Lu P, Sun B, Ho M, Jia S, Ding T, Gao W. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer 2021;9:e001875. [PMID: 33833049 DOI: 10.1136/jitc-2020-001875] [Reference Citation Analysis]
137 Ding X, He M, Chan AWH, Song QX, Sze SC, Chen H, Man MKH, Man K, Chan SL, Lai PBS, Wang X, Wong N. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. Gastroenterology 2020:S0016-5085(20)30659-4. [PMID: 32428506 DOI: 10.1053/j.gastro.2019.09.056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 2021;21:541-57. [PMID: 34326518 DOI: 10.1038/s41568-021-00383-9] [Reference Citation Analysis]
139 Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol R, Solé M, Heikenwälder M, Friedman SL, Sia D, Llovet JM. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Gastroenterology 2019;157:1383-1397.e11. [PMID: 31344396 DOI: 10.1053/j.gastro.2019.07.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
140 Meunier L, Hirsch TZ, Caruso S, Imbeaud S, Bayard Q, Roehrig A, Couchy G, Nault JC, Llovet JM, Blanc JF, Calderaro J, Zucman-Rossi J, Letouzé E. DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology 2021;74:816-34. [PMID: 33713365 DOI: 10.1002/hep.31796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Gingold JA, Zhu D, Lee DF, Kaseb A, Chen J. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends Mol Med. 2018;24:395-411. [PMID: 29530485 DOI: 10.1016/j.molmed.2018.02.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
142 Jiao Y, Li Y, Jiang P, Han W, Liu Y. PGM5: a novel diagnostic and prognostic biomarker for liver cancer. PeerJ. 2019;7:e7070. [PMID: 31218127 DOI: 10.7717/peerj.7070] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
143 Qadan M, Kothary N, Sangro B, Palta M. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Am Soc Clin Oncol Educ Book 2020;40:1-8. [PMID: 32213090 DOI: 10.1200/EDBK_280811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
144 Mo Z, Wang Y, Cao Z, Li P, Zhang S. An Integrative Analysis Reveals the Underlying Association Between CTNNB1 Mutation and Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2020;10:853. [PMID: 32596147 DOI: 10.3389/fonc.2020.00853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Chan LK, Tsui YM, Ho DW, Ng IO. Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol 2021:S1044-579X(21)00050-X. [PMID: 33647386 DOI: 10.1016/j.semcancer.2021.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
146 Qiu X, Li M, Wu L, Xin Y, Mu S, Li T, Song K. Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Cancer Manag Res 2020;12:7983-92. [PMID: 32943932 DOI: 10.2147/CMAR.S233448] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Galle PR, Dufour JF, Peck-Radosavljevic M, Trojan J, Vogel A. Systemic therapy of advanced hepatocellular carcinoma. Future Oncol 2021;17:1237-51. [PMID: 33307782 DOI: 10.2217/fon-2020-0758] [Reference Citation Analysis]
148 Qi X, Schepers E, Avella D, Kimchi ET, Kaifi JT, Staveley-O'Carroll KF, Li G. An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis. J Vis Exp 2019. [PMID: 31566616 DOI: 10.3791/59368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
149 Berman RM, Kelada OJ, Gutsche NT, Natarajan R, Swenson RE, Fu Y, Hong J, Ho M, Choyke PL, Escorcia FE. In Vitro Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency. Cancer Biother Radiopharm 2019;34:498-503. [PMID: 31424293 DOI: 10.1089/cbr.2019.2888] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
150 Zhang J, Wang T, Mu S, Olerile LD, Yu X, Zhang N. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy. Nanomedicine 2017;12:911-25. [DOI: 10.2217/nnm-2016-0402] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
151 Wang K, Duan C, Zou X, Song Y, Li W, Xiao L, Peng J, Yao L, Long Q, Liu L. Increased mediator complex subunit 15 expression is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;15:4303-13. [PMID: 29556287 DOI: 10.3892/ol.2018.7820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
152 Dai Y, Qiang W, Lin K, Gui Y, Lan X, Wang D. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:967-79. [PMID: 33089373 DOI: 10.1007/s00262-020-02743-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
153 Sung PS, Jang JW. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. Int J Mol Sci. 2018;19:3648. [PMID: 30463262 DOI: 10.3390/ijms19113648] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
154 Khan AA, Liu ZK, Xu X. Recent advances in immunotherapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00124-7. [PMID: 34344612 DOI: 10.1016/j.hbpd.2021.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Blumer T, Fofana I, Matter MS, Wang X, Montazeri H, Calabrese D, Coto-Llerena M, Boldanova T, Nuciforo S, Kancherla V, Tornillo L, Piscuoglio S, Wieland S, Terracciano LM, Ng CKY, Heim MH. Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. Hepatol Commun 2019;3:971-86. [PMID: 31334445 DOI: 10.1002/hep4.1365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
156 Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol 2019;12:453-70. [PMID: 30907177 DOI: 10.1080/17512433.2019.1598859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
157 Yan T, Liu F, Gao J, Lu H, Cai J, Zhao X, Sun Y. Multilevel regulation of RUVBL2 expression predicts poor prognosis in hepatocellular carcinoma. Cancer Cell Int 2019;19:249. [PMID: 31572066 DOI: 10.1186/s12935-019-0974-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Jiang J, Liu B, Liu R, Yang W. Overexpression of Taspase 1 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Manag Res 2021;13:2517-37. [PMID: 33758547 DOI: 10.2147/CMAR.S296069] [Reference Citation Analysis]
159 Thompson SM, Wells ML, Andrews JC, Ehman EC, Menias CO, Hallemeier CL, Roberts LR, Venkatesh SK. Venous invasion by hepatic tumors: imaging appearance and implications for management. Abdom Radiol (NY) 2018;43:1947-67. [PMID: 28929197 DOI: 10.1007/s00261-017-1298-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
160 Schneller D, Angel P; Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany, Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany. Cellular Origin of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 1-28. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
161 Hill MA, Alexander WB, Guo B, Kato Y, Patra K, O'Dell MR, McCall MN, Whitney-Miller CL, Bardeesy N, Hezel AF. Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 2018;78:4445-51. [PMID: 29871934 DOI: 10.1158/0008-5472.CAN-17-1123] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
162 Lei Z, Tang X, Si A, Yang P, Wang L, Luo T, Guo G, Zhang Q, Cheng Z. microRNA-454 promotes liver tumor-initiating cell expansion by regulating SOCS6. Exp Cell Res 2020;390:111955. [PMID: 32165166 DOI: 10.1016/j.yexcr.2020.111955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
163 Zhang YG, Niu JT, Wu HW, Si XL, Zhang SJ, Li DH, Bian TT, Li YF, Yan XK. Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy. Anal Cell Pathol (Amst) 2021;2021:6692811. [PMID: 34194957 DOI: 10.1155/2021/6692811] [Reference Citation Analysis]
164 Qi LW, Jia JH, Jiang CH, Hu JM. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma. Front Genet 2020;11:614566. [PMID: 33519919 DOI: 10.3389/fgene.2020.614566] [Reference Citation Analysis]
165 Han R, Feng P, Pang J, Zou D, Li X, Geng C, Li L, Min J, Shi J. A Novel HCC Prognosis Predictor EEF1E1 Is Related to Immune Infiltration and May Be Involved in EEF1E1/ATM/p53 Signaling. Front Oncol 2021;11:700972. [PMID: 34282404 DOI: 10.3389/fonc.2021.700972] [Reference Citation Analysis]
166 Zhu B, Chen JJ, Feng Y, Yang JL, Huang H, Chung WY, Hu YL, Xue WJ. DNMT1-induced miR-378a-3p silencing promotes angiogenesis via the NF-κB signaling pathway by targeting TRAF1 in hepatocellular carcinoma. J Exp Clin Cancer Res 2021;40:352. [PMID: 34749775 DOI: 10.1186/s13046-021-02110-6] [Reference Citation Analysis]
167 Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 2019;129:3324-38. [PMID: 31305264 DOI: 10.1172/JCI126022] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 37.0] [Reference Citation Analysis]
168 Yang S, Yao B, Wu L, Liu Y, Liu K, Xu P, Zheng Y, Deng Y, Zhai Z, Wu Y, Li N, Zhang D, Kang H, Dai Z. Ubiquitin-related molecular classification and risk stratification of hepatocellular carcinoma. Mol Ther Oncolytics 2021;21:207-19. [PMID: 34095460 DOI: 10.1016/j.omto.2021.04.003] [Reference Citation Analysis]
169 Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 [PMID: 34721773 DOI: 10.4251/wjgo.v13.i10.1397] [Reference Citation Analysis]
170 Lin YT, Jeng LB, Chan WL, Su IJ, Teng CF. Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma. Viruses 2021;13:862. [PMID: 34066744 DOI: 10.3390/v13050862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
171 Ezhilarasan D. Mitochondria: A critical hub for hepatic stellate cells activation during chronic liver diseases. Hepatobiliary Pancreat Dis Int 2021;20:315-22. [PMID: 33975780 DOI: 10.1016/j.hbpd.2021.04.010] [Reference Citation Analysis]
172 Huck I, Beggs K, Apte U. Paradoxical Protective Effect of Perfluorooctanesulfonic Acid Against High-Fat Diet-Induced Hepatic Steatosis in Mice. Int J Toxicol 2018;37:383-92. [PMID: 30134762 DOI: 10.1177/1091581818790934] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
173 Savier E, Simon-Gracia L, Charlotte F, Tuffery P, Teesalu T, Scatton O, Rebollo A. Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. Pharmaceutics 2021;13:1631. [PMID: 34683924 DOI: 10.3390/pharmaceutics13101631] [Reference Citation Analysis]
174 Tharehalli U, Svinarenko M, Lechel A. Remodelling and Improvements in Organoid Technology to Study Liver Carcinogenesis in a Dish. Stem Cells Int 2019;2019:3831213. [PMID: 30915124 DOI: 10.1155/2019/3831213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
175 Kuznietsova H, Dziubenko N, Herheliuk T, Prylutskyy Y, Tauscher E, Ritter U, Scharff P. Water-Soluble Pristine C60 Fullerene Inhibits Liver Alterations Associated with Hepatocellular Carcinoma in Rat. Pharmaceutics 2020;12:E794. [PMID: 32842595 DOI: 10.3390/pharmaceutics12090794] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
176 Mauda-Havakuk M, Mikhail AS, Starost MF, Jones EC, Karim B, Kleiner DE, Partanen A, Esparza-Trujillo JA, Bakhutashvili I, Wakim PG, Kassin MT, Lewis AL, Karanian JW, Wood BJ, Pritchard WF. Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model. J Hepatocell Carcinoma 2021;8:71-83. [PMID: 33728278 DOI: 10.2147/JHC.S287800] [Reference Citation Analysis]
177 Tao X, Zuo Q, Ruan H, Wang H, Jin H, Cheng Z, Lv Y, Qin W, Wang C. Argininosuccinate synthase 1 suppresses cancer cell invasion by inhibiting STAT3 pathway in hepatocellular carcinoma. Acta Biochim Biophys Sin (Shanghai) 2019;51:263-76. [PMID: 30883650 DOI: 10.1093/abbs/gmz005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
178 Martín-Sierra C, Martins R, Coucelo M, Abrantes AM, Oliveira RC, Tralhão JG, Botelho MF, Furtado E, Domingues MR, Paiva A, Laranjeira P. Elevated soluble TNFα levels and upregulated TNFα mRNA expression in purified peripheral blood monocyte subsets associated with high-grade hepatocellular carcinoma. J Inflamm (Lond) 2020;17:14. [PMID: 32256215 DOI: 10.1186/s12950-020-00243-7] [Reference Citation Analysis]
179 Xu Y, Zhang Z, Xu D, Yang X, Zhou L, Zhu Y. Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma. Cancer Cell Int 2021;21:409. [PMID: 34344378 DOI: 10.1186/s12935-021-02108-2] [Reference Citation Analysis]
180 Thein HH, Qiao Y, Zaheen A, Jembere N, Sapisochin G, Chan KKW, Yoshida EM, Earle CC. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. PLoS One 2017;12:e0185198. [PMID: 29016627 DOI: 10.1371/journal.pone.0185198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
181 Patten DA, Shetty S. Chronic liver disease: scavenger hunt for novel therapies. Lancet 2018;391:104-5. [PMID: 29353605 DOI: 10.1016/S0140-6736(17)32671-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
182 Hou XJ, Zhao QD, Jing YY, Han ZP, Yang X, Wei LX, Zheng YT, Xie F, Zhang BH. Methylation mediated Gadd45β enhanced the chemosensitivity of hepatocellular carcinoma by inhibiting the stemness of liver cancer cells. Cell Biosci 2017;7:63. [PMID: 29225771 DOI: 10.1186/s13578-017-0189-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
183 Xue JS, Liu H, Meng GX, Ding ZN, Yan LJ, Yao SY, Li HC, Dong ZR, Chen ZQ, Hong JG, Li T. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Immunol Immunother 2021. [PMID: 34750662 DOI: 10.1007/s00262-021-03103-2] [Reference Citation Analysis]
184 Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J Cancer 2016;7:1798-803. [PMID: 27698918 DOI: 10.7150/jca.15618] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
185 Loesch R, Chenane L, Colnot S. ARID2 Chromatin Remodeler in Hepatocellular Carcinoma. Cells 2020;9:E2152. [PMID: 32977645 DOI: 10.3390/cells9102152] [Reference Citation Analysis]
186 Wang H, Wang H, Li K, Li S, Sun B. IGFBP-3 Is the Key Target of Sanguinarine in Promoting Apoptosis in Hepatocellular Carcinoma. Cancer Manag Res 2020;12:1007-15. [PMID: 32104082 DOI: 10.2147/CMAR.S234291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
187 Lin ZL, Ding J, Sun GP, Li D, He SS, Liang XF, Huang XR, Xie J. Application of Paclitaxel-loaded EGFR Peptide-conjugated Magnetic Polymeric Liposomes for Liver Cancer Therapy. Curr Med Sci 2020;40:145-54. [PMID: 32166677 DOI: 10.1007/s11596-020-2158-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
188 Liu Z, Ye J, Khan AA, Chen J, Zhou L, Zheng S, Xu X. Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma. Med Sci Monit 2021;27:e930052. [PMID: 34407065 DOI: 10.12659/MSM.930052] [Reference Citation Analysis]
189 Sun P, Fan X, Hu X, Fu X, Wei Q, Zang Y. circPCNX and Pecanex Promote Hepatocellular Carcinoma Cell Viability by Inhibiting miR-506. Cancer Manag Res 2019;11:10957-67. [PMID: 32099459 DOI: 10.2147/CMAR.S232940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
190 Li H, Liu H, Fu H, Li J, Xu L, Wang G, Wu H. Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:648812. [PMID: 34122408 DOI: 10.3389/fimmu.2021.648812] [Reference Citation Analysis]
191 Sarcognato S, García-Lezana T, Villanueva A. Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;14:62-5. [PMID: 31508222 DOI: 10.1002/cld.810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
192 Wang J, Zhang Q, Shi F, Yadav DK, Hong Z, Wang J, Liang T, Bai X. A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma. Front Genet 2021;12:728476. [PMID: 34603388 DOI: 10.3389/fgene.2021.728476] [Reference Citation Analysis]
193 Alcedo KP, Guerrero A, Basrur V, Fu D, Richardson ML, McLane JS, Tsou CC, Nesvizhskii AI, Welling TH, Lebrilla CB, Otey CA, Kim HJ, Omary MB, Snider NT. Tumor-Selective Altered Glycosylation and Functional Attenuation of CD73 in Human Hepatocellular Carcinoma. Hepatol Commun 2019;3:1400-14. [PMID: 31592495 DOI: 10.1002/hep4.1410] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
194 Hu M, Fu Q, Jing C, Zhang X, Qin T, Pan Y. LncRNA HOTAIR knockdown inhibits glycolysis by regulating miR-130a-3p/HIF1A in hepatocellular carcinoma under hypoxia. Biomed Pharmacother. 2020;125:109703. [PMID: 32062551 DOI: 10.1016/j.biopha.2019.109703] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
195 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel) 2021;13:5018. [PMID: 34638502 DOI: 10.3390/cancers13195018] [Reference Citation Analysis]
196 Zhou W, Zhang S, Cai Z, Gao F, Deng W, Wen Y, Qiu ZW, Hou ZK, Chen XL. A glycolysis-related gene pairs signature predicts prognosis in patients with hepatocellular carcinoma. PeerJ 2020;8:e9944. [PMID: 33062428 DOI: 10.7717/peerj.9944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
197 Tang Y, Yang X, Feng K, Hu C, Li S. High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:174-83. [PMID: 33708434 DOI: 10.21037/jgo-20-534] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
198 Roca Suarez AA, Baumert TF, Lupberger J. Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling. J Hepatol 2018;69:564-6. [PMID: 29937068 DOI: 10.1016/j.jhep.2018.05.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
199 Liu Y, Mao Y, Wang J, Wang J, Lao X, Chen M, Li S. Hepatocellular carcinoma with en bloc diaphragmatic resection: A single-center experience over 14 years. International Journal of Surgery 2018;53:93-7. [DOI: 10.1016/j.ijsu.2018.03.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
200 Duan JL, Nie RC, Xiang ZC, Chen JW, Deng MH, Liang H, Wang FW, Luo RZ, Xie D, Cai MY. Prognostic Model for the Risk Stratification of Early and Late Recurrence in Hepatitis B Virus-Related Small Hepatocellular Carcinoma Patients with Global Histone Modifications. J Hepatocell Carcinoma 2021;8:493-505. [PMID: 34095004 DOI: 10.2147/JHC.S309451] [Reference Citation Analysis]
201 Denk H, Stumptner C, Abuja PM, Zatloukal K. Sequestosome 1/p62-related pathways as therapeutic targets in hepatocellular carcinoma. Expert Opin Ther Targets 2019;23:393-406. [PMID: 30987486 DOI: 10.1080/14728222.2019.1601703] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
202 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
203 Liu H, Zheng S, Hou X, Liu X, Du K, Lv X, Li Y, Yang F, Li W, Sui J. Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects. Cancer Sci 2020;111:1750-60. [PMID: 32061104 DOI: 10.1111/cas.14353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
204 Fan X, Chen G, Li Y, Shi Z, He L, Zhou D, Lin H. The Preoperative Prognostic Nutritional Index in Hepatocellular Carcinoma After Curative Hepatectomy: A Retrospective Cohort Study and Meta-Analysis. J Invest Surg 2021;34:826-33. [PMID: 31818159 DOI: 10.1080/08941939.2019.1698679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
205 Wan LF, Shen JJ, Wang YH, Zhao W, Fang NY, Yuan X, Xue BY. Extracts of Qizhu decoction inhibit hepatitis and hepatocellular carcinoma in vitro and in C57BL/6 mice by suppressing NF-κB signaling. Sci Rep 2019;9:1415. [PMID: 30723284 DOI: 10.1038/s41598-018-38391-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
206 Yang M, Wu X, Li L, Li S, Li N, Mao M, Pan S, Du R, Wang X, Chen M, Xiao N, Zhu X, He G, Zhang L, Huang W, Pan H, Deng L, Chen L, Liang L, Guan J. COMMD10 inhibits tumor progression and induces apoptosis by blocking NF-κB signal and values up BCLC staging in predicting overall survival in hepatocellular carcinoma. Clin Transl Med 2021;11:e403. [PMID: 34047468 DOI: 10.1002/ctm2.403] [Reference Citation Analysis]
207 Nault JC, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology. 2021;73 Suppl 1:115-127. [PMID: 32045030 DOI: 10.1002/hep.31175] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
208 El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492-2502. [PMID: 28434648 DOI: 10.1016/s0140-6736(17)31046-2] [Cited by in Crossref: 1593] [Cited by in F6Publishing: 1024] [Article Influence: 398.3] [Reference Citation Analysis]
209 Du B, Liao H, Zhang S. Expression Pattern and Prognostic Utility of PME-1 in Patients with Hepatocellular Carcinoma. Cancer Manag Res 2020;12:2937-45. [PMID: 32431540 DOI: 10.2147/CMAR.S252873] [Reference Citation Analysis]
210 Tan A, Babak MV, Venkatesan G, Lim C, Klotz KN, Herr DR, Cheong SL, Federico S, Spalluto G, Ong WY, Chen YZ, Loo JSE, Pastorin G. Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer Therapy. Molecules 2019;24:E3661. [PMID: 31614517 DOI: 10.3390/molecules24203661] [Reference Citation Analysis]
211 Gaza A, Fritz V, Malek L, Wormser L, Treiber N, Danner J, Kremer AE, Thasler WE, Siebler J, Meister G, Neurath MF, Hellerbrand C, Bosserhoff AK, Dietrich P. Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11. Neoplasia 2021;23:502-14. [PMID: 33901943 DOI: 10.1016/j.neo.2021.04.001] [Reference Citation Analysis]
212 Lee J, Liao R, Wang G, Yang BH, Luo X, Varki NM, Qiu SJ, Ren B, Fu W, Feng GS. Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions. Cell Rep 2017;21:1870-82. [PMID: 29141219 DOI: 10.1016/j.celrep.2017.10.064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
213 Yang Y, Guo J, Hao Y, Wang F, Li F, Shuang S, Wang J. Silencing of karyopherin α2 inhibits cell growth and survival in human hepatocellular carcinoma. Oncotarget 2017;8:36289-304. [PMID: 28422734 DOI: 10.18632/oncotarget.16749] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
214 Takahashi K, Ofuji K, Hiramatsu K, Nosaka T, Naito T, Matsuda H, Endo K, Higuchi M, Ohtani M, Nemoto T, Nakamoto Y. Circulating tumor cells detected with a microcavity array predict clinical outcome in hepatocellular carcinoma. Cancer Med 2021;10:2300-9. [PMID: 33675149 DOI: 10.1002/cam4.3790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Zeng Z, Lu Q, Liu Y, Zhao J, Zhang Q, Hu L, Shi Z, Tu Y, Xiao Z, Xu Q, Huang D. Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma. Front Oncol 2021;11:641522. [PMID: 34307125 DOI: 10.3389/fonc.2021.641522] [Reference Citation Analysis]
216 Imai K, Yamashita YI, Nakao Y, Matsumoto T, Kinoshita S, Yusa T, Kitano Y, Kaida T, Hayashi H, Baba H. Is Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma Justified in Patients with Impaired Liver Function? Ann Surg Oncol 2021;28:854-62. [PMID: 32740735 DOI: 10.1245/s10434-020-08960-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Zheng D, Williams C, Vold JA, Nguyen JH, Harnois DM, Bagaria SP, McLaughlin SA, Li Z. Regulation of sex hormone receptors in sexual dimorphism of human cancers. Cancer Lett 2018;438:24-31. [PMID: 30223066 DOI: 10.1016/j.canlet.2018.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
218 Yu DC, Chen XY, Li X, Zhou HY, Yu DQ, Yu XL, Hu YC, Zhang RH, Zhang XB, Zhang K, An JD. Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma. Sci Rep 2021;11:11165. [PMID: 34045512 DOI: 10.1038/s41598-021-89628-z] [Reference Citation Analysis]
219 Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol 2021;56:181-90. [PMID: 33392749 DOI: 10.1007/s00535-020-01753-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
220 Zheng LL, Tao CC, Tao ZG, Zhang K, Wu AK, Wu JX, Rong WQ. Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(10): 1136-1148 [DOI: 10.4240/wjgs.v13.i10.1136] [Reference Citation Analysis]
221 Zhang X, Liu S, Dong Q, Xin Y, Xuan S. The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant. J Clin Transl Hepatol 2018;6:326-31. [PMID: 30271746 DOI: 10.14218/JCTH.2018.00022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
222 Rudalska R, Zender L, Dauch D. Exploiting lipotoxicity for the treatment of liver cancer. Br J Cancer 2021. [PMID: 34302061 DOI: 10.1038/s41416-021-01479-7] [Reference Citation Analysis]
223 Song H, Sun N, Lin L, Wei S, Zeng K, Liu W, Wang C, Zhong X, Wang M, Wang S, Zhou B, Lv C, Liu W, Zhao Y. Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma. Cancer Sci 2020;111:3665-78. [PMID: 32745318 DOI: 10.1111/cas.14595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
224 Ma B, Li J, Yang WK, Zhang MG, Xie XD, Bai ZT. N-trans-Feruloyloctopamine Wakes Up BBC3, DDIT3, CDKN1A, and NOXA Signals to Accelerate HCC Cell Apoptosis. Anal Cell Pathol (Amst) 2021;2021:1560307. [PMID: 34123711 DOI: 10.1155/2021/1560307] [Reference Citation Analysis]
225 Chen Y, Li S, Li W, Yang R, Zhang X, Ye Y, Yu J, Ye L, Tang W. Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Sci Rep. 2019;9:7084. [PMID: 31068623 DOI: 10.1038/s41598-019-43572-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
226 Zhang S, Zhou D. Role of the transcriptional coactivators YAP/TAZ in liver cancer. Current Opinion in Cell Biology 2019;61:64-71. [DOI: 10.1016/j.ceb.2019.07.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 19.0] [Reference Citation Analysis]
227 Wang G, Luo X, Liang Y, Kaneko K, Li H, Fu XD, Feng GS. A tumorigenic index for quantitative analysis of liver cancer initiation and progression. Proc Natl Acad Sci U S A 2019:201911193. [PMID: 31843886 DOI: 10.1073/pnas.1911193116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
228 Zhang YL, Xue G, Miao H, Zhou CC, Sun SH, Zhang Y. Folic acid supplementation acts as a chemopreventive factor in tumorigenesis of hepatocellular carcinoma by inducing H3K9Me2-dependent transcriptional repression of LCN2. Oncotarget 2021;12:366-78. [PMID: 33659047 DOI: 10.18632/oncotarget.27136] [Reference Citation Analysis]
229 Kawai T, Yasuchika K, Ishii T, Katayama H, Yoshitoshi EY, Ogiso S, Minami T, Miyauchi Y, Kojima H, Yamaoka R, Kita S, Yasuda K, Sasaki N, Fukumitsu K, Hatano E, Uemoto S. Identification of keratin 19-positive cancer stem cells associating human hepatocellular carcinoma using CYFRA 21-1. Cancer Med 2017;6:2531-40. [PMID: 28965351 DOI: 10.1002/cam4.1211] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
230 Yamada N, Matsushima-Nishiwaki R, Kobayashi K, Tachi J, Kozawa O. GLP-1 reduces the migration of hepatocellular carcinoma cells via suppression of the stress-activated protein kinase/c-Jun N-terminal kinase pathway. Arch Biochem Biophys 2021;703:108851. [PMID: 33771507 DOI: 10.1016/j.abb.2021.108851] [Reference Citation Analysis]
231 Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. Br J Cancer 2021;125:190-9. [PMID: 33824476 DOI: 10.1038/s41416-021-01334-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
232 Chen WS, Liang Y, Zong M, Liu JJ, Kaneko K, Hanley KL, Zhang K, Feng GS. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment. Cell Rep 2021;37:109974. [PMID: 34758313 DOI: 10.1016/j.celrep.2021.109974] [Reference Citation Analysis]
233 Gao X, Wang Y, Li Y, Wang Y, Yan M, Sun H, Chen S, Pan X. Huganpian, a traditional chinese medicine, inhibits liver cancer growth in vitro and in vivo by inducing autophagy and cell cycle arrest. Biomed Pharmacother 2019;120:109469. [PMID: 31698319 DOI: 10.1016/j.biopha.2019.109469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
234 Girardi DM, Pacífico JPM, Guedes de Amorim FPL, Dos Santos Fernandes G, Teixeira MC, Pereira AAL. Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals (Basel) 2020;14:28. [PMID: 33396181 DOI: 10.3390/ph14010028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
235 Huaman J, Naidoo M, Zang X, Ogunwobi OO. Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. Cells 2019;8:E618. [PMID: 31226820 DOI: 10.3390/cells8060618] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
236 Miller B, Chalfant H, Thomas A, Wellberg E, Henson C, McNally MW, Grizzle WE, Jain A, McNally LR. Diabetes, Obesity, and Inflammation: Impact on Clinical and Radiographic Features of Breast Cancer. Int J Mol Sci 2021;22:2757. [PMID: 33803201 DOI: 10.3390/ijms22052757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Zhang GX, Liu YL, Yang M, Huang WS, Xu JH. An aptamer-based, fluorescent and radionuclide dual-modality probe. Biochimie 2020;171-172:55-62. [PMID: 32081705 DOI: 10.1016/j.biochi.2020.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
238 Lu Y, Zhang J, Wu Y. Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis. Mol Med Rep 2021;24:609. [PMID: 34184075 DOI: 10.3892/mmr.2021.12247] [Reference Citation Analysis]
239 Cao J, Jiang H, Zhang R, Ghanam A, Xia H, Zhu Y, Yang Z, Song X. Epigenomic profiling identifies the role of Nr5a2 and CYP1B1 in hepatocellular carcinoma stemness maintenance. Science Bulletin 2019;64:1132-5. [DOI: 10.1016/j.scib.2019.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Zhu Y, Deng M, Xu N, Xie Y, Zhang X. A Tumor Microenvironment Responsive Nanotheranostics Agent for Magnetic Resonance Imaging and Synergistic Photodynamic Therapy/Photothermal Therapy of Liver Cancer. Front Chem 2021;9:650899. [PMID: 33898391 DOI: 10.3389/fchem.2021.650899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Jiao Y, Li Y, Fu Z, Hou L, Chen Q, Cai Y, Jiang P, He M, Yang Z. OGDHL Expression as a Prognostic Biomarker for Liver Cancer Patients. Dis Markers. 2019;2019:9037131. [PMID: 31781311 DOI: 10.1155/2019/9037131] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
242 Peng S, Chen Y, Gong Y, Li Z, Xie R, Lin Y, Zou B, Li J, Zeng L. Predictive value of intratumour inflammatory cytokine mRNA levels of hepatocellular carcinoma patients and activation of two distinct pathways govern IL-8 induced epithelial-mesenchymal transition in human hepatic cancer cell lines. Cytokine 2019;119:81-9. [PMID: 30903867 DOI: 10.1016/j.cyto.2019.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
243 Jia J, Qiao Y, Pilo MG, Cigliano A, Liu X, Shao Z, Calvisi DF, Chen X. Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade. PLoS One 2017;12:e0184068. [PMID: 28877210 DOI: 10.1371/journal.pone.0184068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
244 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
245 Yang QX, Zhong S, He L, Jia XJ, Tang H, Cheng ST, Ren JH, Yu HB, Zhou L, Zhou HZ, Ren F, Hu ZW, Gong R, Huang AL, Chen J. PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway. Cancer Lett 2019;452:90-102. [PMID: 30914208 DOI: 10.1016/j.canlet.2019.03.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
246 Liao X, Yu T, Yang C, Huang K, Wang X, Han C, Huang R, Liu X, Yu L, Zhu G, Su H, Qin W, Deng J, Zeng X, Han B, Han Q, Liu Z, Zhou X, Liu J, Gong Y, Liu Z, Huang J, Lu L, Ye X, Peng T. Comprehensive investigation of key biomarkers and pathways in hepatitis B virus-related hepatocellular carcinoma. J Cancer 2019;10:5689-704. [PMID: 31737106 DOI: 10.7150/jca.31287] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
247 Wu C, Zheng L. Proteomics promises a new era of precision cancer medicine. Signal Transduct Target Ther 2019;4:13. [PMID: 31069119 DOI: 10.1038/s41392-019-0046-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
248 Joerger M, Güller U, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. J Gastrointest Oncol 2019;10:373-8. [PMID: 31032109 DOI: 10.21037/jgo.2018.11.04] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
249 Zhang Q, Rong Y, Yi K, Huang L, Chen M, Wang F. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics 2020;10:12060-71. [PMID: 33204329 DOI: 10.7150/thno.48918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
250 Hu B, Cheng JW, Hu JW, Li H, Ma XL, Tang WG, Sun YF, Guo W, Huang A, Zhou KQ, Gao PT, Cao Y, Qiu SJ, Zhou J, Fan J, Yang XR. KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. J Cancer 2019;10:3914-25. [PMID: 31417635 DOI: 10.7150/jca.31448] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
251 Wang B, Zhu J, Ma X, Wang H, Qiu S, Pan B, Zhou J, Fan J, Yang X, Guo W, Cheng Y. Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma. Clin Chim Acta 2019;495:191-7. [PMID: 30946815 DOI: 10.1016/j.cca.2019.03.1634] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
252 Zhao ZB, Chen F, Bai XF. Long Noncoding RNA MALAT1 Regulates Hepatocellular Carcinoma Growth Under Hypoxia via Sponging MicroRNA-200a. Yonsei Med J 2019;60:727-34. [PMID: 31347327 DOI: 10.3349/ymj.2019.60.8.727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
253 Wu M, Miao H, Fu R, Zhang J, Zheng W. Hepatic Stellate Cell: A Potential Target for Hepatocellular Carcinoma. Curr Mol Pharmacol 2020;13:261-72. [PMID: 32091349 DOI: 10.2174/1874467213666200224102820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
254 Brar G, Greten TF, Graubard BI, McNeel TS, Petrick JL, McGlynn KA, Altekruse SF. Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. Hepatol Commun 2020;4:1541-51. [PMID: 33024922 DOI: 10.1002/hep4.1564] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
255 Sulaimon LA, Adisa RA, Samuel TA, Joel IY, Ayankojo AG, Abdulkareem FB, Olaniyi TO. Molecular mechanism of mitoquinol mesylate in mitigating the progression of hepatocellular carcinoma-in silico and in vivo studies. J Cell Biochem 2021. [PMID: 33909925 DOI: 10.1002/jcb.29937] [Reference Citation Analysis]
256 Wu G, Ju X, Wang Y, Li Z, Gan X. Up-regulation of SNHG6 activates SERPINH1 expression by competitive binding to miR-139-5p to promote hepatocellular carcinoma progression. Cell Cycle 2019;18:1849-67. [PMID: 31258024 DOI: 10.1080/15384101.2019.1629772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
257 Gao J, Dai C, Yu X, Yin XB, Zhou F. microRNA-485-5p inhibits the progression of hepatocellular carcinoma through blocking the WBP2/Wnt signaling pathway. Cell Signal 2020;66:109466. [PMID: 31706018 DOI: 10.1016/j.cellsig.2019.109466] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
258 Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333. [PMID: 31783782 DOI: 10.1186/s40425-019-0824-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 19.5] [Reference Citation Analysis]
259 Chen H, Jia W. Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes Dis 2020;7:320-7. [PMID: 32884986 DOI: 10.1016/j.gendis.2020.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
260 Chen J, Mitra A, Li S, Song S, Nguyen BN, Chen JS, Shin JH, Gough NR, Lin P, Obias V, He AR, Yao Z, Malta TM, Noushmehr H, Latham PS, Su X, Rashid A, Mishra B, Wu RC, Mishra L. Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling. Cancer Res 2020;80:1819-32. [PMID: 32127355 DOI: 10.1158/0008-5472.CAN-19-3116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
261 Woodrell CD, Schiano TD, Goldstein NE. Hepatocellular Carcinoma: A Wrinkle in the Emerging Palliative Care/Oncology Paradigm. JOP 2017;13:404-5. [DOI: 10.1200/jop.2017.022533] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
262 Gao B, Luo J, Liu Y, Su S, Fu S, Yang X, Li B. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma. Int J Nanomedicine 2021;16:4073-85. [PMID: 34163160 DOI: 10.2147/IJN.S308057] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Mohs A, Kuttkat N, Otto T, Youssef SA, De Bruin A, Trautwein C. MyD88-dependent signaling in non-parenchymal cells promotes liver carcinogenesis. Carcinogenesis 2020;41:171-81. [PMID: 30770929 DOI: 10.1093/carcin/bgy173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Wu H, Xing H, Liang L, Huang B, Li C, Lau WY, Zhou Y, Gu W, Wang H, Chen T, Zhang Y, Zeng Y, Pawlik TM, Wang M, Wu M, Shen F, Yang T. Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study. European Journal of Surgical Oncology 2019;45:2360-8. [DOI: 10.1016/j.ejso.2019.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
265 Yang Q, Zhang J, Xu S, Jia C, Meng W, Tang H, Zhang X, Zhang Y, Fu B. Knockdown of PHF5A Inhibits Migration and Invasion of HCC Cells via Downregulating NF-κB Signaling. Biomed Res Int 2019;2019:1621854. [PMID: 30766880 DOI: 10.1155/2019/1621854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
266 Sadeghi S, Bejjani A, Finn RS. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:695-715. [PMID: 31472914 DOI: 10.1016/j.soc.2019.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Wang M, Yu F, Li P. Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E258. [PMID: 30072625 DOI: 10.3390/cancers10080258] [Cited by in Crossref: 54] [Cited by in F6Publishing: 62] [Article Influence: 18.0] [Reference Citation Analysis]
268 Tian M, Yang X, Li Y, Guo S. The Expression of Dynamin 1, 2, and 3 in Human Hepatocellular Carcinoma and Patient Prognosis. Med Sci Monit 2020;26:e923359. [PMID: 32573516 DOI: 10.12659/MSM.923359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI. Liver Radioembolization: An Analysis of Parameters that Influence the Catheter-Based Particle-Delivery via CFD. CMC 2020;27:1600-15. [DOI: 10.2174/0929867325666180622145647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
270 Zhou L, Zhu W, Wang G, Cao X, Zhang X, Chen Q. Investigation of microRNA expression signatures in HCC via microRNA Gene Chip and bioinformatics analysis. Pathology - Research and Practice 2020;216:152982. [DOI: 10.1016/j.prp.2020.152982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Kirchmeyer M, Servais FA, Hamdorf M, Nazarov PV, Ginolhac A, Halder R, Vallar L, Glanemann M, Rubie C, Lammert F, Kreis S, Behrmann I. Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets. J Leukoc Biol 2018;104:987-1002. [DOI: 10.1002/jlb.ma1217-499rr] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
272 Liao J, Zeng D, Li J, Hua Q, Xiao Z, He C, Mao K, Zhu L, Chu Y, Wen W, Zheng L, Wu Y. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatol Int 2020;14:80-95. [DOI: 10.1007/s12072-019-10003-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
273 Landerer S, Kalthoff S, Paulusch S, Strassburg CP. UDP-glucuronosyltransferase polymorphisms affect diethylnitrosamine-induced carcinogenesis in humanized transgenic mice. Cancer Sci 2020;111:4266-75. [PMID: 32860300 DOI: 10.1111/cas.14635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
274 Matsuda M, Seki E. Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis. Semin Liver Dis 2020;40:307-20. [PMID: 32242330 DOI: 10.1055/s-0040-1708876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
275 Gai X, Zhou P, Xu M, Liu Z, Zheng X, Liu Q. Hyperactivation of IL-6/STAT3 pathway leaded to the poor prognosis of post-TACE HCCs by HIF-1α/SNAI1 axis-induced epithelial to mesenchymal transition. J Cancer 2020;11:570-82. [PMID: 31942180 DOI: 10.7150/jca.35631] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
276 Wang C, Wang H, Lieftink C, du Chatinier A, Gao D, Jin G, Jin H, Beijersbergen RL, Qin W, Bernards R. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut 2020;69:727-36. [PMID: 31519701 DOI: 10.1136/gutjnl-2019-318506] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
277 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? Front Oncol 2021;11:696183. [PMID: 34178694 DOI: 10.3389/fonc.2021.696183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
278 Yılmaz Y, Güneş A, Topel H, Atabey N. Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis. J Gastrointest Cancer 2017;48:225-37. [PMID: 28819741 DOI: 10.1007/s12029-017-9958-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
279 Kamimura K, Yokoo T, Abe H, Terai S. Gene Therapy for Liver Cancers: Current Status from Basic to Clinics. Cancers (Basel) 2019;11:E1865. [PMID: 31769427 DOI: 10.3390/cancers11121865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
280 Brown ZJ, Yu SJ, Heinrich B, Ma C, Fu Q, Sandhu M, Agdashian D, Zhang Q, Korangy F, Greten TF. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunol Immunother. 2018;67:1305-1315. [PMID: 29959458 DOI: 10.1007/s00262-018-2190-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 15.3] [Reference Citation Analysis]
281 He M, Hu L, Bai P, Guo T, Liu N, Feng F, Zhang J. LncRNA PCNAP1 Promotes Hepatoma Cell Proliferation through Targeting miR-340-5p and is Associated with Patient Survival. J Oncol 2021;2021:6627173. [PMID: 34007276 DOI: 10.1155/2021/6627173] [Reference Citation Analysis]
282 Wu J, Zhang T, Chen Y, Ha S. MiR-139-5p influences hepatocellular carcinoma cell invasion and proliferation capacities via decreasing SLITRK4 expression. Biosci Rep 2020;40:BSR20193295. [PMID: 32285917 DOI: 10.1042/BSR20193295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
283 Shi C, Zhao Q, Liao B, Dong Z, Wang C, Yang J, Shen W. Anatomic resection and wide resection margin play an important role in hepatectomy for hepatocellular carcinoma with peritumoural micrometastasis. ANZ J Surg 2019;89:E482-6. [PMID: 31618805 DOI: 10.1111/ans.15396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
284 Shankaraiah RC, Callegari E, Guerriero P, Rimessi A, Pinton P, Gramantieri L, Silini EM, Sabbioni S, Negrini M. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene 2019;38:7035-45. [PMID: 31409896 DOI: 10.1038/s41388-019-0942-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
285 Horvat N, Nikolovski I, Long N, Gerst S, Zheng J, Pak LM, Simpson A, Zheng J, Capanu M, Jarnagin WR, Mannelli L, Do RKG. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. Abdom Radiol (NY) 2018;43:169-78. [PMID: 28765978 DOI: 10.1007/s00261-017-1261-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
286 Pollutri D, Gramantieri L, Bolondi L, Fornari F. TP53/MicroRNA Interplay in Hepatocellular Carcinoma. Int J Mol Sci. 2016;17. [PMID: 27918441 DOI: 10.3390/ijms17122029] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
287 Yang J, Li B, Zhao S, Du H, Du Y. Exosomal miR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1. Onco Targets Ther 2020;13:6709-20. [PMID: 32764961 DOI: 10.2147/OTT.S253151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
288 Martin SP, Fako V, Dang H, Dominguez DA, Khatib S, Ma L, Wang H, Zheng W, Wang XW. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:99. [PMID: 32487192 DOI: 10.1186/s13046-020-01605-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
289 Zhao X, Dou J, Cao J, Wang Y, Gao Q, Zeng Q, Liu W, Liu B, Cui Z, Teng L, Zhang J, Zhao C. Uncovering the potential differentially expressed miRNAs as diagnostic biomarkers for hepatocellular carcinoma based on machine learning in The Cancer Genome Atlas database. Oncol Rep 2020;43:1771-84. [PMID: 32236623 DOI: 10.3892/or.2020.7551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
290 Zou WY, El-Serag HB, Sada YH, Temple SL, Sansgiry S, Kanwal F, Davila JA. Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. Dig Dis Sci 2018;63:1173-81. [PMID: 29508165 DOI: 10.1007/s10620-018-4989-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
291 Huang ZL, Li W, Chen QF, Wu PH, Shen LJ. Eight key long non-coding RNAs predict hepatitis virus positive hepatocellular carcinoma as prognostic targets. World J Gastrointest Oncol 2019; 11(11): 983-997 [PMID: 31798779 DOI: 10.4251/wjgo.v11.i11.983] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
292 Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, Qin L, Lu L, Chen J. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC. Hepatology 2021. [PMID: 34036623 DOI: 10.1002/hep.31921] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
293 Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL. Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? Br J Cancer. 2018;118:248-257. [PMID: 29123264 DOI: 10.1038/bjc.2017.386] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
294 Jeng KS, Lu SJ, Wang CH, Chang CF. Liver Fibrosis and Inflammation under the Control of ERK2. Int J Mol Sci 2020;21:E3796. [PMID: 32471201 DOI: 10.3390/ijms21113796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
295 Li W, Chen QF, Huang T, Wu P, Shen L, Huang ZL. Identification and Validation of a Prognostic lncRNA Signature for Hepatocellular Carcinoma. Front Oncol 2020;10:780. [PMID: 32587825 DOI: 10.3389/fonc.2020.00780] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
296 Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI. Numerical investigation of liver radioembolization via computational particle–hemodynamics: The role of the microcatheter distal direction and microsphere injection point and velocity. Journal of Biomechanics 2016;49:3714-21. [DOI: 10.1016/j.jbiomech.2016.09.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
297 Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019;11. [PMID: 31216701 DOI: 10.3390/cancers11060841] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
298 Bresnahan E, Lindblad KE, Ruiz de Galarreta M, Lujambio A. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clin Cancer Res 2020;26:5276-86. [PMID: 32327473 DOI: 10.1158/1078-0432.CCR-19-2923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
299 Liu J, Wang D, Zhou J, Wang L, Zhang N, Zhou L, Zeng J, Liu J, Yang M. N6-methyladenosine reader YTHDC2 and eraser FTO may determine hepatocellular carcinoma prognoses after transarterial chemoembolization. Arch Toxicol 2021;95:1621-9. [PMID: 33713148 DOI: 10.1007/s00204-021-03021-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
300 Takahashi A, Moriguchi M, Seko Y, Shima T, Mitsumoto Y, Takashima H, Kimura H, Fujii H, Ishikawa H, Takaharu Y, Ishiba H, Morita A, Jo M, Nagao Y, Arai M, Hara T, Okajima A, Muramatsu A, Yoshinami N, Nakajima T, Mitsuyoshi H, Umemura A, Nishikawa T, Yamaguchi K, Okanoue T, Itoh Y. Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis. Cancers (Basel) 2020;12:E754. [PMID: 32209994 DOI: 10.3390/cancers12030754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
301 Hernández-Oliveras A, Izquierdo-Torres E, Hernández-Martínez G, Zarain-Herzberg Á, Santiago-García J. Transcriptional and epigenetic landscape of Ca2+-signaling genes in hepatocellular carcinoma. J Cell Commun Signal 2021;15:433-45. [PMID: 33398721 DOI: 10.1007/s12079-020-00597-w] [Reference Citation Analysis]
302 Ye L, Mayerle J, Ziesch A, Reiter FP, Gerbes AL, De Toni EN. The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma. Cell Death Discov 2019;5:86. [PMID: 30962952 DOI: 10.1038/s41420-019-0165-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
303 Cheng Y, Chen T, Yang X, Xue J, Chen J. Atractylon induces apoptosis and suppresses metastasis in hepatic cancer cells and inhibits growth in vivo. Cancer Manag Res 2019;11:5883-94. [PMID: 31388314 DOI: 10.2147/CMAR.S194795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
304 Li F, Wang J, Wu N, Zhang H, Li Z, Wei N. H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA. Biochem Biophys Res Commun 2019;520:93-8. [PMID: 31582208 DOI: 10.1016/j.bbrc.2019.09.082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
305 Takaya H, Namisaki T, Moriya K, Shimozato N, Kaji K, Ogawa H, Ishida K, Tsuji Y, Kaya D, Takagi H, Fujinaga Y, Nishimura N, Sawada Y, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. World J Gastroenterol 2020; 26(45): 7232-7241 [PMID: 33362379 DOI: 10.3748/wjg.v26.i45.7232] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
306 Laparra J, Fotschki B, Haros C. Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model. Oncotarget 2019;10:760-72. [PMID: 30774778 DOI: 10.18632/oncotarget.26605] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
307 Zhao X, Qin W, Jiang Y, Yang Z, Yuan B, Dai R, Shen H, Chen Y, Fu J, Wang H. ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma. NPJ Precis Oncol 2020;4:7. [PMID: 32219176 DOI: 10.1038/s41698-020-0111-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
308 Tong H, Wei B, Chen S, Xie YM, Zhang MG, Zhang LH, Huang ZY, Tang CW. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget 2017;8:48303-12. [PMID: 28430638 DOI: 10.18632/oncotarget.15684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
309 Straub K, Husen P, Baba HA, Trippler M, Wedemeyer H, Herzer K. Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice. Cancer Med 2019;8:3793-802. [PMID: 31144474 DOI: 10.1002/cam4.2162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
310 Muranushi R, Araki K, Yokobori T, Chingunjav B, Hoshino K, Dolgormaa G, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Shimoda Y, Sano R, Oyama T, Saeki H, Shirabe K. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci 2021;112:3314-23. [PMID: 34080242 DOI: 10.1111/cas.15004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
311 Liu Y, Wu Y, Liu S, Dai Y. Long Non-Coding RNA TRIM52-AS1 Promotes Growth and Metastasis via miR-218-5p/ROBO1 in Hepatocellular Carcinoma. Cancer Manag Res 2021;13:547-58. [PMID: 33519234 DOI: 10.2147/CMAR.S286205] [Reference Citation Analysis]
312 Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S, Piscuoglio S, Dill MT, Camargo FD, Christofori G, Tang F. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med 2021;:e14351. [PMID: 34664408 DOI: 10.15252/emmm.202114351] [Reference Citation Analysis]
313 Xie Q, Guo H, He P, Deng H, Gao Y, Dong N, Niu W, Liu T, Li M, Wang S, Wu Y, Li JL. Tspan5 promotes epithelial-mesenchymal transition and tumour metastasis of hepatocellular carcinoma by activating Notch signalling. Mol Oncol 2021. [PMID: 33955149 DOI: 10.1002/1878-0261.12980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
314 Wang J, Sun P, Chen Y, Yao H, Wang S. Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells. Sci Rep 2018;8:10923. [PMID: 30026540 DOI: 10.1038/s41598-018-29199-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
315 Buranupakorn T, Thangsuk P, Patumanond J, Phinyo P. Emulation of a Target Trial to Evaluate the Causal Effect of Palliative Care Consultation on the Survival Time of Patients with Hepatocellular Carcinoma. Cancers (Basel) 2021;13:992. [PMID: 33673534 DOI: 10.3390/cancers13050992] [Reference Citation Analysis]
316 Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther 2016; 7(4): 477-489 [PMID: 27867681 DOI: 10.4292/wjgpt.v7.i4.477] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 63] [Article Influence: 13.4] [Reference Citation Analysis]
317 Liu Y, Liu X, Gu Y, Lu H. A novel RNA binding protein-associated prognostic model to predict overall survival in hepatocellular carcinoma patients. Medicine (Baltimore) 2021;100:e26491. [PMID: 34398005 DOI: 10.1097/MD.0000000000026491] [Reference Citation Analysis]
318 Martins-Filho SN, Paiva C, Azevedo RS, Alves VAF. Histological Grading of Hepatocellular Carcinoma-A Systematic Review of Literature. Front Med (Lausanne). 2017;4:193. [PMID: 29209611 DOI: 10.3389/fmed.2017.00193] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
319 Zhang Y, Zhu Z, Huang S, Zhao Q, Huang C, Tang Y, Sun C, Zhang Z, Wang L, Chen H, Chen M, Ju W, He X. lncRNA XIST regulates proliferation and migration of hepatocellular carcinoma cells by acting as miR-497-5p molecular sponge and targeting PDCD4. Cancer Cell Int 2019;19:198. [PMID: 31384173 DOI: 10.1186/s12935-019-0909-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
320 Castelli G, Pelosi E, Testa U. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) 2017;9:E127. [PMID: 28930164 DOI: 10.3390/cancers9090127] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 11.8] [Reference Citation Analysis]
321 Gavini J, Dommann N, Jakob MO, Keogh A, Bouchez LC, Karkampouna S, Julio MK, Medova M, Zimmer Y, Schläfli AM, Tschan MP, Candinas D, Stroka D, Banz V. Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death Dis 2019;10:749. [PMID: 31582741 DOI: 10.1038/s41419-019-1989-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
322 Li Y, Chen X, Huang H, Li G, Liao L, Yuan T, Deng S. Identification Of Novel lncRNAs For Detection Of HBV-Associated Hepatocellular Carcinoma. Onco Targets Ther 2019;12:10199-211. [PMID: 31819509 DOI: 10.2147/OTT.S230377] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
323 Zhang J, Fang C, Qu M, Wu H, Wang X, Zhang H, Ma H, Zhang Z, Huang Y, Shi L, Liang S, Gao Z, Song W, Wang X. CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents. Front Pharmacol 2018;9:1042. [PMID: 30258365 DOI: 10.3389/fphar.2018.01042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
324 Yu MC, Liu JX, Ma XL, Hu B, Fu PY, Sun HX, Tang WG, Yang ZF, Qiu SJ, Zhou J, Fan J, Xu Y. Differential network analysis depicts regulatory mechanisms for hepatocellular carcinoma from diverse backgrounds. Future Oncol 2019;15:3917-34. [PMID: 31729887 DOI: 10.2217/fon-2019-0275] [Reference Citation Analysis]
325 Laskowski J, Renner B, Pickering MC, Serkova NJ, Smith-Jones PM, Clambey ET, Nemenoff RA, Thurman JM. Complement factor H-deficient mice develop spontaneous hepatic tumors. J Clin Invest 2020;130:4039-54. [PMID: 32369457 DOI: 10.1172/JCI135105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
326 Wang H, Jiang W, Wang H, Wei Z, Li H, Yan H, Han P. Identification of Mutation Landscape and Immune Cell Component for Liver Hepatocellular Carcinoma Highlights Potential Therapeutic Targets and Prognostic Markers. Front Genet 2021;12:737965. [PMID: 34603396 DOI: 10.3389/fgene.2021.737965] [Reference Citation Analysis]
327 Fang T, Fang Y, Xu X, He M, Zhao Z, Huang P, Yuan F, Guo M, Yang B, Xia J. Actinidia chinensis Planch root extract attenuates proliferation and metastasis of hepatocellular carcinoma by inhibiting epithelial-mesenchymal transition. J Ethnopharmacol 2019;231:474-85. [PMID: 30415058 DOI: 10.1016/j.jep.2018.11.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
328 Pelizzaro F, Cardin R, Penzo B, Pinto E, Vitale A, Cillo U, Russo FP, Farinati F. Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now? Cancers (Basel) 2021;13:2274. [PMID: 34068786 DOI: 10.3390/cancers13092274] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
329 Liu T, Xie XL, Zhou X, Chen SX, Wang YJ, Shi LP, Chen SJ, Wang YJ, Wang SL, Zhang JN, Dou SY, Jiang XY, Cui RL, Jiang HQ. Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4667-4686 [PMID: 34366628 DOI: 10.3748/wjg.v27.i28.4667] [Reference Citation Analysis]
330 Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4876. [PMID: 34638361 DOI: 10.3390/cancers13194876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
331 Thompson SM, Garg I, Ehman EC, Sheedy SP, Bookwalter CA, Carter RE, Roberts LR, Venkatesh SK. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. Br J Radiol 2018;91:20180345. [PMID: 30074820 DOI: 10.1259/bjr.20180345] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
332 Kong XY, Vik ES, Nawaz MS, Berges N, Dahl TB, Vågbø C, Suganthan R, Segers F, Holm S, Quiles-Jiménez A, Gregersen I, Fladeby C, Aukrust P, Bjørås M, Klungland A, Halvorsen B, Alseth I. Deletion of Endonuclease V suppresses chemically induced hepatocellular carcinoma. Nucleic Acids Res 2020;48:4463-79. [PMID: 32083667 DOI: 10.1093/nar/gkaa115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
333 Xu L, Feng X, Hao X, Wang P, Zhang Y, Zheng X, Li L, Ren S, Zhang M, Xu M. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. J Exp Clin Cancer Res 2019;38:98. [PMID: 30795787 DOI: 10.1186/s13046-019-1041-2] [Cited by in Crossref: 78] [Cited by in F6Publishing: 91] [Article Influence: 39.0] [Reference Citation Analysis]
334 Wang M, Wei K, Qian B, Feiler S, Lemekhova A, Büchler MW, Hoffmann K. HSP70-eIF4G Interaction Promotes Protein Synthesis and Cell Proliferation in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2262. [PMID: 32823513 DOI: 10.3390/cancers12082262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
335 Deng M, Li S, Mei J, Lin W, Zou J, Wei W, Guo R. High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. Genes (Basel) 2021;12:876. [PMID: 34200261 DOI: 10.3390/genes12060876] [Reference Citation Analysis]
336 Zhang Y, Zhang L, Xu Y, Wu X, Zhou Y, Mo J. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. J Cell Physiol 2020;235:9304-16. [PMID: 32330311 DOI: 10.1002/jcp.29730] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 33.0] [Reference Citation Analysis]
337 Zhao W, Jiang L, Fang T, Fang F, Liu Y, Zhao Y, You Y, Zhou H, Su X, Wang J, Liu S, Chen Y, Wan J, Huang X. β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation. Front Oncol 2021;11:747282. [PMID: 34676172 DOI: 10.3389/fonc.2021.747282] [Reference Citation Analysis]
338 Deng Z, Wang J, Xu B, Jin Z, Wu G, Zeng J, Peng M, Guo Y, Wen Z. Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma. Biomed Res Int 2019;2019:2408348. [PMID: 31828095 DOI: 10.1155/2019/2408348] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
339 Kwan SY, Jiao J, Qi J, Wang Y, Wei P, McCormick JB, Fisher-Hoch SP, Beretta L. Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican-American Population of South Texas. Hepatol Commun. 2020;4:555-568. [PMID: 32258950 DOI: 10.1002/hep4.1490] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
340 Liu Z, Li S, Ma T, Zeng J, Zhou X, Li H, Tang M, Liu X, Li F, Jiang B, Zhao M, Chen Y. Secreted TRAIL gene-modified adipose-derived stem cells exhibited potent tumor-suppressive effect in hepatocellular carcinoma cells. Immun Inflamm Dis 2021;9:144-56. [PMID: 33156578 DOI: 10.1002/iid3.372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
341 Qiao W, Wang H, Zhang X, Luo K. Proline-rich protein 11 silencing inhibits hepatocellular carcinoma growth and epithelial-mesenchymal transition through β-catenin signaling. Gene 2019;681:7-14. [PMID: 30248355 DOI: 10.1016/j.gene.2018.09.036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
342 Yokoyama-Mashima S, Yogosawa S, Kanegae Y, Hirooka S, Yoshida S, Horiuchi T, Ohashi T, Yanaga K, Saruta M, Oikawa T, Yoshida K. Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer. Cancer Lett 2019;451:100-9. [PMID: 30851422 DOI: 10.1016/j.canlet.2019.02.046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
343 Li H, Huang H, Li S, Mei H, Cao T, Lu Q. Long non-coding RNA ADAMTS9-AS2 inhibits liver cancer cell proliferation, migration and invasion. Exp Ther Med 2021;21:559. [PMID: 33850531 DOI: 10.3892/etm.2021.9991] [Reference Citation Analysis]
344 Bassaganyas L, Pinyol R, Esteban-Fabró R, Torrens L, Torrecilla S, Willoughby CE, Franch-Expósito S, Vila-Casadesús M, Salaverria I, Montal R, Mazzaferro V, Camps J, Sia D, Llovet JM. Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clin Cancer Res 2020;26:6350-61. [PMID: 32873569 DOI: 10.1158/1078-0432.CCR-20-1497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
345 Liang J, Zhi Y, Deng W, Zhou W, Li X, Cai Z, Zhu Z, Zeng J, Wu W, Dong Y, Huang J, Zhang Y, Xu S, Feng Y, Ding F, Zhang J. Development and validation of ferroptosis-related lncRNAs signature for hepatocellular carcinoma. PeerJ 2021;9:e11627. [PMID: 34178478 DOI: 10.7717/peerj.11627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
346 Zeng J, Lin K, Liu H, Huang Y, Guo P, Zeng Y, Zeng J, Liu J. Prognosis Factors of Young Patients Undergoing Curative Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma: A Multicenter Study. Cancer Manag Res 2020;12:6597-606. [PMID: 32848453 DOI: 10.2147/CMAR.S261368] [Reference Citation Analysis]
347 Fang C, Li W, Yin R, Zhu D, Liu X, Wu H, Wang Q, Wang W, Bai Q, Chen B, Yao X, Chen Y. Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway. Sci Rep 2021;11:16507. [PMID: 34389740 DOI: 10.1038/s41598-021-93055-5] [Reference Citation Analysis]
348 Rimassa L, Pressiani T, Merle P. Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer. 2019;8:427-446. [PMID: 31799201 DOI: 10.1159/000499765] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 16.5] [Reference Citation Analysis]
349 Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5232. [PMID: 32718047 DOI: 10.3390/ijms21155232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Fa X, Song P, Fu Y, Deng Y, Liu K. Long non-coding RNA VPS9D1-AS1 facilitates cell proliferation, migration and stemness in hepatocellular carcinoma. Cancer Cell Int 2021;21:131. [PMID: 33627127 DOI: 10.1186/s12935-020-01741-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
351 Fornari F, Giovannini C, Piscaglia F, Gramantieri L. Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. J Hepatocell Carcinoma 2021;8:741-57. [PMID: 34239844 DOI: 10.2147/JHC.S285726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
352 Labbozzetta M, Notarbartolo M, Poma P. Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View. Int J Mol Sci 2020;21:E3070. [PMID: 32349210 DOI: 10.3390/ijms21093070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
353 Leng S, Xie F, Liu J, Shen J, Quan G, Wen T. LLGL2 Increases Ca2+ Influx and Exerts Oncogenic Activities via PI3K/AKT Signaling Pathway in Hepatocellular Carcinoma. Front Oncol 2021;11:683629. [PMID: 34178676 DOI: 10.3389/fonc.2021.683629] [Reference Citation Analysis]
354 Chen SZ, Ling Y, Yu LX, Song YT, Chen XF, Cao QQ, Yu H, Chen C, Tang JJ, Fan ZC, Miao YS, Dong YP, Tao JY, Monga SPS, Wen W, Wang HY. 4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-α. Clin Transl Med 2021;11:e379. [PMID: 33931972 DOI: 10.1002/ctm2.379] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
355 Ma YS, Liu JB, Lin L, Zhang H, Wu JJ, Shi Y, Jia CY, Zhang DD, Yu F, Wang HM, Yin YZ, Jiang XH, Wang PY, Tian LL, Cao PS, Wu XM, Lu HM, Gu LP, Zhang JJ, Cong GJ, Luo P, Zhong XM, Cai B, Shi MX, Zhang SQ, Li L, Zhang WJ, Liu Y, Li ZZ, Wu TM, Wu ZJ, Wang GR, Lv ZW, Ling CC, Chu KJ, Fu D. Exosomal microRNA-15a from mesenchymal stem cells impedes hepatocellular carcinoma progression via downregulation of SALL4. Cell Death Discov 2021;7:224. [PMID: 34455417 DOI: 10.1038/s41420-021-00611-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
356 Floudas CS, Brar G, Greten TF. Immunotherapy: Current Status and Future Perspectives. Dig Dis Sci 2019;64:1030-40. [DOI: 10.1007/s10620-019-05516-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
357 Simoes CC, Thung SN, Fiel MI, Sung MW, Schwartz ME, Ward SC. Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Mod Pathol 2021;34:823-33. [PMID: 32989224 DOI: 10.1038/s41379-020-00679-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
358 Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transpl 2018;24:369-79. [PMID: 29140601 DOI: 10.1002/lt.24977] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
359 Bell MM, Gutsche NT, King AP, Baidoo KE, Kelada OJ, Choyke PL, Escorcia FE. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma. Molecules 2020;26:E4. [PMID: 33374953 DOI: 10.3390/molecules26010004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
360 Wei X, Zhao L, Ren R, Ji F, Xue S, Zhang J, Liu Z, Ma Z, Wang XW, Wong L, Liu N, Shi J, Guo X, Roessler S, Zheng X, Ji J. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma. Hepatology 2021;73:1381-98. [PMID: 32609900 DOI: 10.1002/hep.31448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
361 Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, Daian F, Audebert S, Dono R, Lozano A, Gregoire D, Hibner U, Allende DS, Apte SS, Maina F. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol 2021;74:893-906. [PMID: 33197513 DOI: 10.1016/j.jhep.2020.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
362 Yamada R, Bassaco B, Bracewell S, Volin S, Collins H, Hannegan C, Guimarares M. Combined conventional transarterial chemoembolization with Mitomycin and percutaneous ablation for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2020;11:298-303. [PMID: 32399271 DOI: 10.21037/jgo.2019.01.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Tsai SC, Lin CC, Shih TC, Tseng RJ, Yu MC, Lin YJ, Hsieh SY. The miR-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma. Mol Carcinog 2017;56:2035-47. [PMID: 28383782 DOI: 10.1002/mc.22657] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
364 Tabu K, Mawatari S, Oda K, Taniyama O, Toyodome A, Ijuin S, Sakae H, Kumagai K, Kanmura S, Ido A. Highly sensitive Lens culinaris agglutinin-reactive fraction of α-fetoprotein is a predictive marker for hepatocarcinogenesis in long-term observation of patients with chronic liver disease. Mol Clin Oncol 2021;15:174. [PMID: 34276993 DOI: 10.3892/mco.2021.2336] [Reference Citation Analysis]
365 Cheng Z, Lei Z, Yang P, Si A, Xiang D, Tang X, Guo G, Zhou J, Hüser N. Exosome-transmitted p120-catenin suppresses hepatocellular carcinoma progression via STAT3 pathways. Mol Carcinog 2019;58:1389-99. [PMID: 30997702 DOI: 10.1002/mc.23022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
366 Zhang ZY, Lu M, Liu ZK, Li H, Yong YL, Zhang RY, Chen ZN, Bian H. Rab11a regulates MMP2 expression by activating the PI3K/AKT pathway in human hepatocellular carcinoma cells. Pathol Res Pract 2020;216:153046. [PMID: 32825931 DOI: 10.1016/j.prp.2020.153046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
367 Wang Q, Li X, Qian B, Hu K, Liu B. Fluorescence imaging in the surgical management of liver cancers: Current status and future perspectives. Asian J Surg 2021:S1015-9584(21)00567-4. [PMID: 34656410 DOI: 10.1016/j.asjsur.2021.08.063] [Reference Citation Analysis]
368 Xu J, Cheng X, Tan L, Fu C, Ahmed M, Tian J, Dou J, Zhou Q, Ren X, Wu Q, Tang S, Zhou H, Meng X, Yu J, Liang P. Microwave Responsive Nanoplatform via P-Selectin Mediated Drug Delivery for Treatment of Hepatocellular Carcinoma with Distant Metastasis. Nano Lett 2019;19:2914-27. [DOI: 10.1021/acs.nanolett.8b05202] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
369 Al-Harazi O, Kaya IH, Al-Eid M, Alfantoukh L, Al Zahrani AS, Al Sebayel M, Kaya N, Colak D. Identification of Gene Signature as Diagnostic and Prognostic Blood Biomarker for Early Hepatocellular Carcinoma Using Integrated Cross-Species Transcriptomic and Network Analyses. Front Genet 2021;12:710049. [PMID: 34659334 DOI: 10.3389/fgene.2021.710049] [Reference Citation Analysis]
370 Wei J, Fang DL, Zhou W, He YF. N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes. J Gastrointest Oncol 2021;12:1860-72. [PMID: 34532134 DOI: 10.21037/jgo-21-378] [Reference Citation Analysis]
371 Chianchiano P, Pezhouh MK, Kim A, Luchini C, Cameron A, Weiss MJ, He J, Voltaggio L, Oshima K, Anders RA, Wood LD. Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. Hum Pathol 2018;72:127-34. [PMID: 29180252 DOI: 10.1016/j.humpath.2017.11.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
372 Zhou KQ, Sun YF, Cheng JW, Du M, Ji Y, Wang PX, Hu B, Guo W, Gao Y, Yin Y, Huang JF, Zhou J, Fan J, Yang XR. Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine 2020;62:103107. [PMID: 33181461 DOI: 10.1016/j.ebiom.2020.103107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Wang Y, Hu J, Xiang D, Peng X, You Q, Mao Y, Hua D, Yin J. Targeted nanosystem combined with chemo-photothermal therapy for hepatocellular carcinoma treatment. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2020;596:124711. [DOI: 10.1016/j.colsurfa.2020.124711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
374 Yi PS, Hu CJ, Li CH, Yu F. Clinical value of artificial intelligence in hepatocellular carcinoma: Current status and prospect. Artif Intell Gastroenterol 2021; 2(2): 42-55 [DOI: 10.35712/aig.v2.i2.42] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
375 Zhang C, Yang H, Pan L, Zhao G, Zhang R, Zhang T, Xiao Z, Tong Y, Zhang Y, Hu R, Pandol SJ, Han YP. Hepatitis B Virus X Protein (HBx) Suppresses Transcription Factor EB (TFEB) Resulting in Stabilization of Integrin Beta 1 (ITGB1) in Hepatocellular Carcinoma Cells. Cancers (Basel) 2021;13:1181. [PMID: 33803301 DOI: 10.3390/cancers13051181] [Reference Citation Analysis]
376 Saviano A, Roehlen N, Virzì A, Roca Suarez AA, Hoshida Y, Lupberger J, Baumert TF. Stromal and Immune Drivers of Hepatocarcinogenesis. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 317-31. [DOI: 10.1007/978-3-030-21540-8_15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci 2021;22:5421. [PMID: 34063828 DOI: 10.3390/ijms22115421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
378 Cho KJ, Shin SY, Moon H, Kim BK, Ro SW. Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer. Transl Oncol 2021;14:101158. [PMID: 34174688 DOI: 10.1016/j.tranon.2021.101158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
379 Tian M, Shi Y, Liu W, Fan J. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Sci China Life Sci 2019;62:1138-43. [PMID: 31119560 DOI: 10.1007/s11427-018-9446-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
380 Zhu C, Luo X, Wu J, Liu Y, Liu L, Ma S, Xie R, Wang S, Ji W. TM4SF1, a binding protein of DVL2 in hepatocellular carcinoma, positively regulates beta-catenin/TCF signalling. J Cell Mol Med 2021;25:2356-64. [PMID: 31876386 DOI: 10.1111/jcmm.14787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
381 Chen QF, Li W, Wu P, Shen L, Huang ZL. Alternative splicing events are prognostic in hepatocellular carcinoma. Aging (Albany NY) 2019;11:4720-35. [PMID: 31301224 DOI: 10.18632/aging.102085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
382 von Felden J. New systemic agents for hepatocellular carcinoma: an update 2020. Curr Opin Gastroenterol 2020;36:177-83. [PMID: 32101985 DOI: 10.1097/MOG.0000000000000626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
383 Gao R, Buechel D, Kalathur RKR, Morini MF, Coto-Llerena M, Ercan C, Piscuoglio S, Chen Q, Blumer T, Wang X, Dazert E, Heim MH, Hall MN, Tang F, Christofori G. USP29-mediated HIF1α stabilization is associated with Sorafenib resistance of hepatocellular carcinoma cells by upregulating glycolysis. Oncogenesis 2021;10:52. [PMID: 34272356 DOI: 10.1038/s41389-021-00338-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
384 Zhu L, Li T, Ma X, Qiu Y, Ma X, Lin Y, Han L, Qin C. A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Sci Rep 2017;7:8954. [PMID: 28827721 DOI: 10.1038/s41598-017-09358-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
385 Cardarelli-Leite L, Hadjivassiliou A, Klass D, Chung J, Ho SGF, Lim HJ, Kim PTW, Mujoomdar A, Liu DM. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Curr Oncol 2020;27:S144-51. [PMID: 33343208 DOI: 10.3747/co.27.7171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
386 Deng M, Li SH, Guo RP. Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. Am Surg 2021;:31348211054532. [PMID: 34743609 DOI: 10.1177/00031348211054532] [Reference Citation Analysis]
387 Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World J Hepatol 2021; 13(9): 1132-1142 [PMID: 34630880 DOI: 10.4254/wjh.v13.i9.1132] [Reference Citation Analysis]
388 In der Stroth L, Tharehalli U, Günes C, Lechel A. Telomeres and Telomerase in the Development of Liver Cancer. Cancers (Basel) 2020;12:E2048. [PMID: 32722302 DOI: 10.3390/cancers12082048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
389 Makol A, Kaur H, Sharma S, Kanthaje S, Kaur R, Chakraborti A. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line. Clin Mol Hepatol. 2020;26:45-53. [PMID: 31564085 DOI: 10.3350/cmh.2019.0031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
390 Kanogawa N, Ogasawara S, Ooka Y, Inoue M, Wakamatsu T, Yokoyama M, Maruta S, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kanzaki H, Maeda T, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Saito T, Motoyama T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Takemura R, Nozaki-Taguchi N, Shiroh I, Yokosuka O, Kato N. Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. JGH Open 2021;5:273-9. [PMID: 33553667 DOI: 10.1002/jgh3.12483] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Kang X, Wang H, Li Y, Xiao Y, Zhao L, Zhang T, Zhou S, Zhou X, Li Y, Shou Z, Chen C, Li B. Alantolactone induces apoptosis through ROS-mediated AKT pathway and inhibition of PINK1-mediated mitophagy in human HepG2 cells. Artificial Cells, Nanomedicine, and Biotechnology 2019;47:1961-70. [DOI: 10.1080/21691401.2019.1593854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
392 Hu JW, Chen B, Zhang J, Qi YP, Liang JH, Zhong JH, Xiang BD. Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma. J Cancer 2020;11:6437-44. [PMID: 33033527 DOI: 10.7150/jca.47532] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
393 Xu J, Yan B, Zhang L, Zhou L, Zhang J, Yu W, Dong X, Yao L, Shan L. Theabrownin Induces Apoptosis and Tumor Inhibition of Hepatocellular Carcinoma Huh7 Cells Through ASK1-JNK-c-Jun Pathway. Onco Targets Ther 2020;13:8977-87. [PMID: 32982289 DOI: 10.2147/OTT.S254693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
394 Chung AS, Mettlen M, Ganguly D, Lu T, Wang T, Brekken RA, Hsiehchen D, Zhu H. Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. Cancer Prev Res (Phila) 2020;13:911-22. [PMID: 32839204 DOI: 10.1158/1940-6207.CAPR-20-0200] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
395 Kalathil SG, Hutson A, Barbi J, Iyer R, Thanavala Y. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight 2019;4:130116. [PMID: 31391334 DOI: 10.1172/jci.insight.130116] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
396 Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020;38:2960-70. [PMID: 32716739 DOI: 10.1200/JCO.20.00808] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 100.0] [Reference Citation Analysis]
397 Zhou M, Yang H, Learned RM, Tian H, Ling L. Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun 2017;8:15433. [PMID: 28508871 DOI: 10.1038/ncomms15433] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 17.3] [Reference Citation Analysis]
398 Tsai YC, Sou FM, Liu YW, Wu YJ, Yong CC, Chen DW, Huang PY, Cho WR, Chuang CH, Hsiao CC, Hu TH, Tsai MC. Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterol 2021;21:386. [PMID: 34666694 DOI: 10.1186/s12876-021-01944-w] [Reference Citation Analysis]
399 Huo TX, Wang XP, Yu Z, Kong B, He Y, Guo QL, Zhang XB, Qiang L. Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression. Acta Pharmacol Sin 2021. [PMID: 34117368 DOI: 10.1038/s41401-021-00695-4] [Reference Citation Analysis]
400 Sun YF, Wang PX, Cheng JW, Gong ZJ, Huang A, Zhou KQ, Hu B, Gao PT, Cao Y, Qiu SJ, Zhou J, Fan J, Guo W, Yang XR. Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. Cancer Cytopathol 2020;128:733-45. [PMID: 32501632 DOI: 10.1002/cncy.22304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
401 Dai T, Peng L, Lin G, Li Y, Yao J, Deng Y, Li H, Wang G, Liu W, Yang Y, Chen G, Wang G. Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma. J Gastrointest Oncol 2019;10:1049-63. [PMID: 31949922 DOI: 10.21037/jgo.2019.09.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
402 Tsai MC, Huang CC, Wei YC, Liu TT, Lin MT, Yi LN, Lin PR, Wang CC, Chu TH, Hsiao CC, Hu TH, Tai MH. Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E2060. [PMID: 32192213 DOI: 10.3390/ijms21062060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Tefera J, Revzin M, Chapiro J, Savic LJ, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma-a new variant of liver cancer: clinical, pathological and radiological correlation. J Clin Pathol. 2021;74:31-35. [PMID: 32430483 DOI: 10.1136/jclinpath-2020-206574] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
404 Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1017-24. [PMID: 32762583 DOI: 10.1080/17474124.2020.1807939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
405 Qiu W, Wang B, Gao Y, Tian Y, Tian M, Chen Y, Xu L, Yao T, Li P, Yang P. Targeting Histone Deacetylase 6 Reprograms Interleukin‐17‐Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma. Hepatology 2020;71:1967-87. [DOI: 10.1002/hep.30960] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
406 Fu L, Xie H, Huang J, Chen L. Rapid determination of trace elements in serum of hepatocellular carcinoma patients by inductively coupled plasma tandem mass spectrometry. Analytica Chimica Acta 2020;1112:1-7. [DOI: 10.1016/j.aca.2020.03.054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
407 Duong LM, Cai H, Shrubsole MJ, Bailey CE, Idrees K, Shu XO. Outcomes of robotic-assisted liver surgery versus laparoscopic liver surgery for treatment of stage I hepatocellular carcinoma. Cancer 2021. [PMID: 34674225 DOI: 10.1002/cncr.33979] [Reference Citation Analysis]
408 Herrero A, Nadalin S, Panaro F. Liver transplantation for irresectable colorectal liver metastases: still a contraindication? Hepatobiliary Surg Nutr 2018;7:475-8. [PMID: 30652092 DOI: 10.21037/hbsn.2018.08.04] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
409 Han M, Lu H, Han K, Yuan X, Liu S, Wang Y, Zhao J, Liang P, Cheng J. XTP8 promotes hepatocellular carcinoma growth by forming a positive feedback loop with FOXM1 oncogene. Biochem Biophys Res Commun 2019;515:455-61. [PMID: 31164201 DOI: 10.1016/j.bbrc.2019.05.164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
410 Matsushima-nishiwaki R, Toyoda H, Takamatsu R, Yasuda E, Okuda S, Maeda A, Kaneoka Y, Yoshimi N, Kumada T, Kozawa O. Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2017;1863:1629-39. [DOI: 10.1016/j.bbadis.2017.04.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
411 Leone P, Solimando AG, Fasano R, Argentiero A, Malerba E, Buonavoglia A, Lupo LG, De Re V, Silvestris N, Racanelli V. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines (Basel) 2021;9:532. [PMID: 34065489 DOI: 10.3390/vaccines9050532] [Reference Citation Analysis]
412 Xing J, Tian Y, Ji W, Wang X. Comprehensive evaluation of SPATS2 expression and its prognostic potential in liver cancer. Medicine (Baltimore) 2020;99:e19230. [PMID: 32118724 DOI: 10.1097/MD.0000000000019230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
413 Joechle K, Guenzle J, Hellerbrand C, Strnad P, Cramer T, Neumann UP, Lang SA. Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer. World J Gastrointest Oncol 2021; 13(11): 1632-1647 [DOI: 10.4251/wjgo.v13.i11.1632] [Reference Citation Analysis]
414 Ma ZJ, Wang Y, Li HF, Liu MH, Bi FR, Ma L, Ma H, Yan HL. LncZEB1-AS1 regulates hepatocellular carcinoma bone metastasis via regulation of the miR-302b-EGFR-PI3K-AKT axis. J Cancer 2020;11:5118-28. [PMID: 32742459 DOI: 10.7150/jca.45995] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
415 Mody K, Abou-Alfa GK. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. Curr Treat Options Oncol. 2019;20:3. [PMID: 30635732 DOI: 10.1007/s11864-019-0601-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
416 Bugide S, Green MR, Wajapeyee N. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells. Proc Natl Acad Sci U S A 2018;115:E3509-18. [PMID: 29581297 DOI: 10.1073/pnas.1802691115] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 17.0] [Reference Citation Analysis]
417 Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597. [PMID: 28934265 DOI: 10.1371/journal.pone.0184597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 10.5] [Reference Citation Analysis]
418 Wang Y, Pei L, Yue Z, Jia M, Wang H, Cao LL. The Potential of Serum Exosomal hsa_circ_0028861 as the Novel Diagnostic Biomarker of HBV-Derived Hepatocellular Cancer. Front Genet 2021;12:703205. [PMID: 34367259 DOI: 10.3389/fgene.2021.703205] [Reference Citation Analysis]
419 Cho WR, Wang CC, Tsai MY, Chou CK, Liu YW, Wu YJ, Lin MT, Chen KD, Chuang CH, Huang PY, Hu TH, Tsai MC. Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients. PLoS One 2021;16:e0247231. [PMID: 33661912 DOI: 10.1371/journal.pone.0247231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
420 Damiris K, Abbad H, Pyrsopoulos N. Cellular based treatment modalities for unresectable hepatocellular carcinoma. World J Clin Oncol 2021; 12(5): 290-308 [PMID: 34131562 DOI: 10.5306/wjco.v12.i5.290] [Reference Citation Analysis]
421 Sun Y, Zhang Z. In Silico Identification of Crucial Genes and Specific Pathways in Hepatocellular Cancer. Genet Test Mol Biomarkers 2020;24:296-308. [PMID: 32384023 DOI: 10.1089/gtmb.2019.0242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
422 Li J, Zhong X, Wang X, Xu F, Yang J, Lu J, Liu C, Lu J. miR-93 regulates liver tumor initiating cells expansion and predicts chemotherapeutic response of patients. Arch Biochem Biophys 2021;703:108871. [PMID: 33831356 DOI: 10.1016/j.abb.2021.108871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
423 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018; 24(40): 4536-4547 [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
424 Lin WF, Zhong MF, Zhang YR, Wang H, Zhao HT, Cheng BB, Ling CQ. Prognostic Role of Platelet-to-Lymphocyte Ratio in Hepatocellular Carcinoma with Different BCLC Stages: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2018;2018:5670949. [PMID: 30158964 DOI: 10.1155/2018/5670949] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
425 Chen W, Mao Y, Liu C, Wu H, Chen S. Exosome in Hepatocellular Carcinoma: an update. J Cancer 2021;12:2526-36. [PMID: 33854614 DOI: 10.7150/jca.54566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
426 Fang A, Liu Z, Liao G, Chen P, Wang X, Zhang D, Luo Y, Long J, Zhong R, Zhou Z, Xu Y, Xu X, Ling W, Chen M, Zhang Y, Zhu H. Serum folate concentrations at diagnosis are associated with hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort study. Br J Nutr 2019;121:1376-88. [DOI: 10.1017/s0007114519000734] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
427 Taebi A, Pillai RM, Roudsari BS, Vu CT, Roncali E. Computational Modeling of the Liver Arterial Blood Flow for Microsphere Therapy: Effect of Boundary Conditions. Bioengineering (Basel) 2020;7:E64. [PMID: 32610459 DOI: 10.3390/bioengineering7030064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
428 Molina-Sánchez P, Lujambio A. Strategies for HCC target discovery. Aging (Albany NY) 2017;9:1088-9. [PMID: 28455974 DOI: 10.18632/aging.101233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
429 Lei C, Wang Q, Tang N, Wang K. GSTZ1-1 downregulates Wnt/β-catenin signalling in hepatocellular carcinoma cells. FEBS Open Bio 2020;10:6-17. [PMID: 31782257 DOI: 10.1002/2211-5463.12769] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
430 Wang G, Liu J, Cai Y, Chen J, Xie W, Kong X, Huang W, Guo H, Zhao X, Lu Y, Niu L, Li X, Zhang H, Lei C, Lei Z, Yin J, Hu H, Yu F, Nie Y, Xia L, Wu K. Loss of Barx1 promotes hepatocellular carcinoma metastasis through up-regulating MGAT5 and MMP9 expression and indicates poor prognosis. Oncotarget 2017;8:71867-80. [PMID: 29069753 DOI: 10.18632/oncotarget.18288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
431 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
432 Lee DY, Kim EH. Therapeutic Effects of Amino Acids in Liver Diseases: Current Studies and Future Perspectives. J Cancer Prev 2019;24:72-8. [PMID: 31360687 DOI: 10.15430/JCP.2019.24.2.72] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 10.5] [Reference Citation Analysis]
433 Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 2018;8:9227. [PMID: 29907753 DOI: 10.1038/s41598-018-27521-y] [Cited by in Crossref: 506] [Cited by in F6Publishing: 602] [Article Influence: 168.7] [Reference Citation Analysis]
434 Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therap Adv Gastroenterol 2018;11:1756284818808086. [PMID: 30377451 DOI: 10.1177/1756284818808086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
435 Tan S, Li H, Zhang W, Shao Y, Liu Y, Guan H, Wu J, Kang Y, Zhao J, Yu Q, Gu Y, Ding K, Zhang M, Qian W, Zhu Y, Cai H, Chen C, Lobie PE, Zhao X, Sun J, Zhu T. NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression. Oncogene 2018;37:4887-900. [PMID: 29780166 DOI: 10.1038/s41388-018-0280-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 13.7] [Reference Citation Analysis]
436 Saha J, Bae J, Wang SY, Lu H, Chappell LJ, Gopal P, Davis AJ. Ablating putative Ku70 phosphorylation sites results in defective DNA damage repair and spontaneous induction of hepatocellular carcinoma. Nucleic Acids Res 2021;49:9836-50. [PMID: 34428289 DOI: 10.1093/nar/gkab743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
437 Mou SJ, Yang PF, Liu YP, Xu N, Jiang WW, Yue WJ. BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma. Life Sci 2020;242:117177. [PMID: 31870774 DOI: 10.1016/j.lfs.2019.117177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
438 Wu LM, Zhang LL, Chen XH, Zheng SS. Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers? Hepatobiliary Pancreat Dis Int. 2019;18:117-124. [PMID: 30655073 DOI: 10.1016/j.hbpd.2019.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
439 [DOI: 10.1101/620773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
440 Wang MD, Li C, Li J, Zhang WG, Jiang WQ, Yu JJ, Xing H, Wu H, Han J, Li ZL, Xu XF, Chen TH, Zhou YH, Gu WM, Wang H, Zeng YY, Zhang YM, Pawlik TM, Lau WY, Wu MC, Yang JM, Shen F, Yang T. Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort Study. Oncologist 2019;24:e730-9. [PMID: 31127021 DOI: 10.1634/theoncologist.2018-0898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
441 Ferrara-Romeo I, Martínez P, Blasco MA. Mice lacking RAP1 show early onset and higher rates of DEN-induced hepatocellular carcinomas in female mice. PLoS One 2018;13:e0204909. [PMID: 30307978 DOI: 10.1371/journal.pone.0204909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
442 Prejac J, Kekez D, Belev B, Kocić L, Bulimbašić S, Pleština S. Leukocytoclastic vasculitis associated with sorafenib treatment for hepatocellular carcinoma. Anticancer Drugs 2020;31:76-9. [PMID: 31567309 DOI: 10.1097/CAD.0000000000000840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
443 Zeng T, Tang Z, Liang L, Suo D, Li L, Li J, Yuan Y, Guan XY, Li Y. PDSS2-Del2, a new variant of PDSS2, promotes tumor cell metastasis and angiogenesis in hepatocellular carcinoma via activating NF-κB. Mol Oncol 2020;14:3184-97. [PMID: 33064899 DOI: 10.1002/1878-0261.12826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
444 Li Y, He X, Zhang X, Xu Y, Chen W, Liu X, Xu X. RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma. Clin Exp Med 2021. [PMID: 34275027 DOI: 10.1007/s10238-021-00742-8] [Reference Citation Analysis]
445 Liu QQ, Liu YW, Xie YK, Zhang JH, Song CX, Wang JZ, Xie BH. Amplification of DDR2 mediates sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma. Cell Biol Int 2021;45:1906-16. [PMID: 33969575 DOI: 10.1002/cbin.11625] [Reference Citation Analysis]
446 Hong WF, Gu YJ, Wang N, Xia J, Zhou HY, Zhan K, Cheng MX, Cai Y. Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:301-14. [PMID: 34221916 DOI: 10.14218/JCTH.2020.00132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Zhao Y, Yang B, Chen D, Zhou X, Wang M, Jiang J, Wei L, Chen Z. Combined identification of ARID1A, CSMD1, and SENP3 as effective prognostic biomarkers for hepatocellular carcinoma. Aging (Albany NY) 2021;13:4696-712. [PMID: 33558447 DOI: 10.18632/aging.202586] [Reference Citation Analysis]
448 Reiter FP, Hadjamu NJ, Nagdyman N, Zachoval R, Mayerle J, De Toni EN, Kaemmerer H, Denk G. Congenital heart disease-associated liver disease: a narrative review. Cardiovasc Diagn Ther 2021;11:577-90. [PMID: 33968635 DOI: 10.21037/cdt-20-595] [Reference Citation Analysis]
449 Chen TW, Yin FF, Yuan YM, Guan DX, Zhang E, Zhang FK, Jiang H, Ma N, Wang JJ, Ni QZ, Qiu L, Feng J, Zhang XL, Bao Y, Wang K, Cheng SQ, Wang XF, Wang X, Li JJ, Xie D. CHML promotes liver cancer metastasis by facilitating Rab14 recycle. Nat Commun 2019;10:2510. [PMID: 31175290 DOI: 10.1038/s41467-019-10364-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
450 Nishida T, Kataoka H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31510063 DOI: 10.3390/cancers11091339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
451 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 49.0] [Reference Citation Analysis]
452 Gao M, Liu D. CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice. Cancer Biol Ther 2017;18:505-12. [PMID: 28513320 DOI: 10.1080/15384047.2017.1323597] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
453 Du X, Zhang Y. Integrated Analysis of Immunity- and Ferroptosis-Related Biomarker Signatures to Improve the Prognosis Prediction of Hepatocellular Carcinoma. Front Genet 2020;11:614888. [PMID: 33391356 DOI: 10.3389/fgene.2020.614888] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
454 Zhao B, Hu S, Xiao Q, Fan S, Yu X, Li C, Dong P, Zheng J. Expression of NOTCH receptors and ligands and prognosis of hepatocellular carcinoma. Biomark Med 2020;14:1631-9. [PMID: 33336594 DOI: 10.2217/bmm-2020-0138] [Reference Citation Analysis]
455 Lee J, Joo I, Lee DH, Jeon SK, Lee JM. Clinical outcomes of patients with a high alpha-fetoprotein level but without evident recurrence on CT or MRI in surveillance after curative-intent treatment for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:597-606. [PMID: 32812065 DOI: 10.1007/s00261-020-02707-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
456 Tong M, Wong TL, Zhao H, Zheng Y, Xie YN, Li CH, Zhou L, Che N, Yun JP, Man K, Lee TK, Cai Z, Ma S. Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer. Cell Rep 2021;36:109617. [PMID: 34433044 DOI: 10.1016/j.celrep.2021.109617] [Reference Citation Analysis]
457 Kan A, Le Y, Zhang YF, Duan FT, Zhong XP, Lu LH, Ling YH, Guo RP. ELTD1 Function in Hepatocellular Carcinoma is Carcinoma-Associated Fibroblast-Dependent. J Cancer 2018;9:2415-27. [PMID: 30026838 DOI: 10.7150/jca.24406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
458 Lee YG, Jeon TI. Modulation of the Autophagy-lysosomal Pathway in Hepatocellular Carcinoma Using Small Molecules. Molecules 2020;25:E1580. [PMID: 32235537 DOI: 10.3390/molecules25071580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
459 Liao J, Jin H, Li S, Xu L, Peng Z, Wei G, Long J, Guo Y, Kuang M, Zhou Q, Peng S. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:454. [PMID: 31694662 DOI: 10.1186/s13046-019-1419-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
460 Rudalska R, Harbig J, Snaebjornsson MT, Klotz S, Zwirner S, Taranets L, Heinzmann F, Kronenberger T, Forster M, Cui W, D’artista L, Einig E, Hinterleitner M, Schmitz W, Dylawerska A, Kang T, Poso A, Rosenfeldt MT, Malek NP, Bitzer M, Laufer S, Pichler BJ, Popov N, Schulze A, Zender L, Dauch D. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer 2021;2:201-17. [DOI: 10.1038/s43018-020-00168-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
461 Yalçınkaya B, Güzel E, Taştekin D, Pençe S. Role of mir-33a, mir-203b, mir361-3p, and mir-424 in hepatocellular carcinoma. Turk J Med Sci 2021;51:638-43. [PMID: 33098283 DOI: 10.3906/sag-2004-214] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
462 Krstic J, Galhuber M, Schulz TJ, Schupp M, Prokesch A. p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. Int J Mol Sci 2018;19:E921. [PMID: 29558460 DOI: 10.3390/ijms19030921] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
463 Zhao H, Xu J, Huang W, Zhan G, Zhao Y, Chen H, Yang X. Spatiotemporally Light-Activatable Platinum Nanocomplexes for Selective and Cooperative Cancer Therapy. ACS Nano 2019;13:6647-61. [DOI: 10.1021/acsnano.9b00972] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
464 Wang Q, Liang N, Yang T, Li Y, Li J, Huang Q, Wu C, Sun L, Zhou X, Cheng X, Zhao L, Wang G, Chen Z, He X, Liu C. DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer. J Hepatol 2021:S0168-8278(21)01845-6. [PMID: 34217777 DOI: 10.1016/j.jhep.2021.06.025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
465 Fan Y, Bazai SK, Daian F, Arechederra M, Richelme S, Temiz NA, Yim A, Habermann BH, Dono R, Largaespada DA, Maina F. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis. Journal of Hepatology 2019;70:470-82. [DOI: 10.1016/j.jhep.2018.11.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
466 Pfohl U, Pflaume A, Regenbrecht M, Finkler S, Graf Adelmann Q, Reinhard C, Regenbrecht CRA, Wedeken L. Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed. Cells 2021;10:928. [PMID: 33920536 DOI: 10.3390/cells10040928] [Reference Citation Analysis]
467 Shibata O, Kamimura K, Ko M, Sakai N, Abe H, Morita S, Mizusawa T, Sato H, Sakamaki A, Terai S. Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature. Intern Med 2021;60:1709-15. [PMID: 33390501 DOI: 10.2169/internalmedicine.6580-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
468 Kurhe Y, Caputo M, Cansby E, Xia Y, Kumari S, Anand SK, Howell BW, Marschall HU, Mahlapuu M. Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00208-3. [PMID: 34624527 DOI: 10.1016/j.jcmgh.2021.09.018] [Reference Citation Analysis]
469 Guo G, Lei Z, Tang X, Ma W, Si A, Yang P, Li Q, Geng Z, Zhou J, Cheng Z. External Validation of Six Liver Functional Reserve Models to predict Posthepatectomy Liver Failure after Major Resection for Hepatocellular Carcinoma. J Cancer 2021;12:5260-7. [PMID: 34335942 DOI: 10.7150/jca.58726] [Reference Citation Analysis]
470 Kamath GR, Taioli E, N Egorova N, Llovet JM, Perumalswami PV, Weiss JJ, Schwartz M, Ewala S, Bickell NA. Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors. Front Oncol 2018;8:220. [PMID: 29963497 DOI: 10.3389/fonc.2018.00220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
471 Wu X, Wang Q, Lu Y, Zhang J, Yin H, Yi Y. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Sci Rep 2021;11:6069. [PMID: 33727662 DOI: 10.1038/s41598-021-85688-3] [Reference Citation Analysis]
472 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers (Basel) 2021;13:3961. [PMID: 34439116 DOI: 10.3390/cancers13163961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
473 Ye L, Kriegl L, Reiter FP, Munker SM, Itzel T, Teufel A, Ziesch A, Török HP, Kirchner T, Gerbes AL, Guba M, Mayerle J, De Toni EN. Prognostic Significance and Functional Relevance of Olfactomedin 4 in Early-Stage Hepatocellular Carcinoma. Clin Transl Gastroenterol 2020;11:e00124. [PMID: 31990698 DOI: 10.14309/ctg.0000000000000124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
474 He C, Jaffar Ali D, Aseervatham G SB, Sun B, Xiao Z. Microvesicles - promising tiny players' of cancer stem cells targeted liver cancer treatments: The interesting interactions and therapeutic aspects. Pharmacol Res 2021;169:105609. [PMID: 33852962 DOI: 10.1016/j.phrs.2021.105609] [Reference Citation Analysis]
475 Sefrioui D, Verdier V, Savoye-Collet C, Beaussire L, Ghomadi S, Gangloff A, Goria O, Riachi G, Montialoux H, Schwarz L, Tuech JJ, Frebourg T, Michel P, Sarafan-Vasseur N, Di Fiore F. Circulating DNA changes are predictive of disease progression after transarterial chemoembolization. Int J Cancer 2021. [PMID: 34622951 DOI: 10.1002/ijc.33829] [Reference Citation Analysis]
476 Li J, Xia T, Cao J, He D, Chen Z, Liang B, Song J. RP11-295G20.2 facilitates hepatocellular carcinoma progression via the miR-6884-3p/CCNB1 pathway. Aging (Albany NY) 2020;12:14918-32. [PMID: 32687483 DOI: 10.18632/aging.103552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
477 Jiao X, Qian X, Wu L, Li B, Wang Y, Kong X, Xiong L. microRNA: The Impact on Cancer Stemness and Therapeutic Resistance. Cells 2019;9:E8. [PMID: 31861404 DOI: 10.3390/cells9010008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
478 Narsinh KH, Duncan DP, Newton IG, Minocha J, Rose SC. Liver-directed therapy for hepatocellular carcinoma. Abdom Radiol (NY). 2018;43:203-217. [PMID: 29230556 DOI: 10.1007/s00261-017-1435-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
479 Fan D, Liu C, Li L, Lu C, Zhao N, Shu J, He X, Lu A. Deciphering Antitumor Mechanism of Pien Tze Huang in Mice of Hepatocellular Carcinoma Based on Proteomics. J Immunol Res 2020;2020:4876251. [PMID: 33344655 DOI: 10.1155/2020/4876251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
480 Zhang N, Jin W, Zhou S, Yang JD, Harmsen WS, Giama NH, Wongjarupong N, Heimbach JK, Watt KD, Malhi H, Therneau TM, Roberts LR. Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. Cancer Med 2018;7:5870-8. [PMID: 30453389 DOI: 10.1002/cam4.1797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
481 Lopez-Lopez V, Robles-Campos R, Brusadin R, Lopez-Conesa A, de la Peña J, Caballero A, Arevalo-Perez J, Navarro-Barrios A, Gómez P, Parrilla-Paricio P. ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization. Ann Transl Med 2019;7:691. [PMID: 31930092 DOI: 10.21037/atm.2019.10.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
482 Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz ME, Llovet JM. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J Hepatol. 2017;67:1222-1231. [PMID: 28843658 DOI: 10.1016/j.jhep.2017.08.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
483 Ding X, He M, Chan AWH, Song QX, Sze SC, Chen H, Man MKH, Man K, Chan SL, Lai PBS, Wang X, Wong N. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. Gastroenterology. 2019;157:1630-1645.e6. [PMID: 31560893 DOI: 10.1053/j.gastro.2019.09.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 22.5] [Reference Citation Analysis]
484 Song Y, Xing H, Zhou L, Zhang N, Yang M. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma. Arch Toxicol 2021;95:3063-70. [PMID: 34251499 DOI: 10.1007/s00204-021-03119-8] [Reference Citation Analysis]
485 Mao B, Zhang L, Ning P, Ding F, Wu F, Lu G, Geng Y, Ma J. Preoperative prediction for pathological grade of hepatocellular carcinoma via machine learning-based radiomics.Eur Radiol. 2020;30:6924-6932. [PMID: 32696256 DOI: 10.1007/s00330-020-07056-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
486 Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34163045 DOI: 10.1038/s41575-021-00465-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
487 Ma Y, Wen J, Wang J, Wang C, Zhang Y, Zhao L, Li J, Feng X. Asiaticoside Antagonizes Proliferation and Chemotherapeutic Drug Resistance in Hepatocellular Carcinoma (HCC) Cells. Med Sci Monit 2020;26:e924435. [PMID: 32862187 DOI: 10.12659/MSM.924435] [Reference Citation Analysis]
488 He Q, He X, Deng B, Shi C, Lin L, Liu P, Yang Z, Yang S, Xu Z. Sorafenib and indocyanine green co-loaded in photothermally sensitive liposomes for diagnosis and treatment of advanced hepatocellular carcinoma. J Mater Chem B 2018;6:5823-34. [PMID: 32254989 DOI: 10.1039/c8tb01641k] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
489 Unfried JP, Fortes P. LncRNAs in HCV Infection and HCV-Related Liver Disease. Int J Mol Sci 2020;21:E2255. [PMID: 32214045 DOI: 10.3390/ijms21062255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
490 Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state: Liver Cancer in the United States. CA: A Cancer Journal for Clinicians 2017;67:273-89. [DOI: 10.3322/caac.21402] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 20.3] [Reference Citation Analysis]
491 Massalha H, Bahar Halpern K, Abu-Gazala S, Jana T, Massasa EE, Moor AE, Buchauer L, Rozenberg M, Pikarsky E, Amit I, Zamir G, Itzkovitz S. A single cell atlas of the human liver tumor microenvironment. Mol Syst Biol 2020;16:e9682. [PMID: 33332768 DOI: 10.15252/msb.20209682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
492 Nahon P, Cobat A. Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet 2020;139:855-63. [PMID: 32100095 DOI: 10.1007/s00439-020-02136-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
493 Mehta KJ, Sharp PA. Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells. Sci Rep 2020;10:21926. [PMID: 33318518 DOI: 10.1038/s41598-020-78348-5] [Reference Citation Analysis]
494 Turpin A, de Baere T, Heurgué A, Le Malicot K, Ollivier-Hourmand I, Lecomte T, Perrier H, Vergniol J, Sefrioui D, Rinaldi Y, Edeline J, Jouve JL, Silvain C, Becouarn Y, Dauvois B, Baconnier M, Debette-Gratien M, Deplanque G, Dharancy S, Lepage C, Hebbar M; PRODIGE 16 investigators Collaborators. Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study. Clin Res Hepatol Gastroenterol 2021;45:101464. [PMID: 32576496 DOI: 10.1016/j.clinre.2020.05.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
495 Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang SL, Yang S, Gong Z, Lai PBS, Chen GG. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol. 2018;10:1758835918816287. [PMID: 30622654 DOI: 10.1177/1758835918816287] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
496 Lv L, Zhao Y, Wei Q, Zhao Y, Yi Q. Downexpression of HSD17B6 correlates with clinical prognosis and tumor immune infiltrates in hepatocellular carcinoma. Cancer Cell Int 2020;20:210. [PMID: 32514254 DOI: 10.1186/s12935-020-01298-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
497 Cassol F, Portal L, Richelme S, Dupont M, Boursier Y, Arechederra M, Auphan-Anezin N, Chasson L, Laprie C, Fernandez S, Balasse L, Lamballe F, Dono R, Guillet B, Lawrence T, Morel C, Maina F. Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography. iScience 2019;21:68-83. [PMID: 31655257 DOI: 10.1016/j.isci.2019.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
498 Liu C, Miao X, Wang Y, Wen L, Cheng X, Kong D, Zhao P, Song D, Wang X, Ding X, Xia H, Wang W, Sun Q, Gong W. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma. Cancer Sci 2020;111:3503-15. [PMID: 32726482 DOI: 10.1111/cas.14588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
499 Wang C, Yang M, Zhao J, Li X, Xiao X, Zhang Y, Jin X, Liao M. Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma. J Cell Physiol 2019;234:10899-906. [DOI: 10.1002/jcp.27905] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
500 Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020;20:220-30. [PMID: 31437349 DOI: 10.1111/ajt.15576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
501 Mocan T, Sparchez Z, Craciun R, Bora CN, Leucuta DC. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol 2019;21:702-12. [PMID: 30387047 DOI: 10.1007/s12094-018-1975-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
502 Hao X, Xin R, Dong W. Decreased serum exosomal miR-320a expression is an unfavorable prognostic factor in patients with hepatocellular carcinoma. J Int Med Res 2020;48:300060519896144. [PMID: 32339037 DOI: 10.1177/0300060519896144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
503 Jiao J, Niu W, Wang Y, Baggerly K, Ye Y, Wu X, Davenport D, Almeda JL, Betancourt-Garcia MM, Forse RA, Stevenson HL, Watt GP, McCormick JB, Fisher-Hoch SP, Beretta L. Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas. Cancer Prev Res (Phila) 2018;11:103-12. [PMID: 29089331 DOI: 10.1158/1940-6207.CAPR-17-0235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
504 Wang C, Jin H, Gao D, Wang L, Evers B, Xue Z, Jin G, Lieftink C, Beijersbergen RL, Qin W, Bernards R. A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma. Cell Res 2018;28:690-2. [PMID: 29507396 DOI: 10.1038/s41422-018-0020-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
505 Park J, Cho J, Lim JH, Lee MH, Kim J. Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis. Target Oncol. 2019;14:395-403. [PMID: 31290003 DOI: 10.1007/s11523-019-00651-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
506 Bartneck M, Schrammen PL, Möckel D, Govaere O, Liepelt A, Krenkel O, Ergen C, McCain MV, Eulberg D, Luedde T, Trautwein C, Kiessling F, Reeves H, Lammers T, Tacke F. The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers. Cell Mol Gastroenterol Hepatol 2019;7:371-90. [PMID: 30704985 DOI: 10.1016/j.jcmgh.2018.10.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
507 Luo YH, Tang W, Zhang X, Tan Z, Guo WL, Zhao N, Pang SM, Dang YW, Rong MH, Cao J. Promising significance of the association of miR-204-5p expression with clinicopathological features of hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e7545. [PMID: 28746200 DOI: 10.1097/MD.0000000000007545] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
508 Alenezi AO, Krishna S, Mendiratta-Lala M, Kielar AZ. Imaging and Management of Liver Cancer. Semin Ultrasound CT MR 2020;41:122-38. [PMID: 32446427 DOI: 10.1053/j.sult.2019.12.002] [Reference Citation Analysis]
509 Murray B, Barbier-Torres L, Fan W, Mato JM, Lu SC. Methionine adenosyltransferases in liver cancer. World J Gastroenterol 2019; 25(31): 4300-4319 [PMID: 31496615 DOI: 10.3748/wjg.v25.i31.4300] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
510 Xia L, Wang S, Zhang H, Yang Y, Wei J, Shi Y, Zou C, Liu J, Luo M, Huang A, Wang D. The HBx and HBc of hepatitis B virus can influence Id1 and Id3 by reducing their transcription and stability. Virus Res 2020;284:197973. [PMID: 32305567 DOI: 10.1016/j.virusres.2020.197973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
511 Allaire M, Rautou P, Codogno P, Lotersztajn S. Autophagy in liver diseases: Time for translation? Journal of Hepatology 2019;70:985-98. [DOI: 10.1016/j.jhep.2019.01.026] [Cited by in Crossref: 88] [Cited by in F6Publishing: 93] [Article Influence: 44.0] [Reference Citation Analysis]
512 Chen YL, Lin PY, Ming YZ, Huang WC, Chen RF, Chen PM, Chu PY. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients. BMC Cancer 2017;17:474. [PMID: 28687090 DOI: 10.1186/s12885-017-3460-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
513 Li L, Guo X, Peng X, Zhang H, Liu Y, Li H, He X, Shi D, Xiong B, Zhao Y, Zheng C, Yang X. Radiofrequency-responsive dual-valent gold nanoclusters for enhancing synergistic therapy of tumor ablation and artery embolization. Nano Today 2020;35:100934. [DOI: 10.1016/j.nantod.2020.100934] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
514 Altshuler PJ, Dang H, Frank AM, Shah AP, Glorioso J, Zhan T, Rios Diaz A, Shaheen O, Ramirez CB, Maley WR, Bodzin AS. Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allografts and Nonalcoholic Steatohepatitis. Liver Transpl 2021. [PMID: 34564931 DOI: 10.1002/lt.26313] [Reference Citation Analysis]
515 Dreval K, Tryndyak V, de Conti A, Beland FA, Pogribny IP. Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis. Front Genet 2019;10:486. [PMID: 31191608 DOI: 10.3389/fgene.2019.00486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
516 Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther 2021;6:75. [PMID: 33619259 DOI: 10.1038/s41392-021-00484-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
517 Wu Q, Xu C, Zeng X, Zhang Z, Yang B, Rao Z. Tumor suppressor role of sFRP‑4 in hepatocellular carcinoma via the Wnt/β‑catenin signaling pathway. Mol Med Rep 2021;23:336. [PMID: 33760186 DOI: 10.3892/mmr.2021.11975] [Reference Citation Analysis]
518 Dai T, Li L, Qi W, Liu B, Jiang Z, Song J, Hua H. Balanophorin B inhibited glycolysis with the involvement of HIF-1α. Life Sci 2021;267:118910. [PMID: 33359671 DOI: 10.1016/j.lfs.2020.118910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
519 Matsushita J, Suzuki T, Okamura K, Ichihara G, Nohara K. Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changes. Environ Health Prev Med 2020;25:31. [PMID: 32703154 DOI: 10.1186/s12199-020-00871-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
520 Zhang Q, Su R, Shan C, Gao C, Wu P. Non-SMC Condensin I Complex, Subunit G (NCAPG) is a Novel Mitotic Gene Required for Hepatocellular Cancer Cell Proliferation and Migration. Oncol Res. 2018;26:269-276. [PMID: 29046167 DOI: 10.3727/096504017x15075967560980] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
521 Mossanen JC, Kohlhepp M, Wehr A, Krenkel O, Liepelt A, Roeth AA, Möckel D, Heymann F, Lammers T, Gassler N, Hermann J, Jankowski J, Neumann UP, Luedde T, Trautwein C, Tacke F. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4+ T-Cell-Dependent Control of Senescence. Gastroenterology 2019;156:1877-1889.e4. [PMID: 30710528 DOI: 10.1053/j.gastro.2019.01.247] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
522 Cho WR, Hung CH, Chen CH, Lin CC, Wang CC, Liu YW, Wu YJ, Yong CC, Chen KD, Tsai YC, Hu TH, Tsai MC. Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery. Sci Rep 2020;10:7290. [PMID: 32350365 DOI: 10.1038/s41598-020-64354-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
523 Woodrell CD, Hansen L, Schiano TD, Goldstein NE. Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults. Clin Ther 2018;40:512-25. [PMID: 29571567 DOI: 10.1016/j.clinthera.2018.02.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
524 Long Y, Yan R, Li K, Luo L, Zeng Q, Tan L, Zhang M, Zheng R, Xu E. Radiofrequency ablation of liver cancers adjacent to the gallbladder without gallbladder isolation under contrast-enhanced ultrasound monitoring: a preliminary study. Int J Hyperthermia 2019;36:139-45. [PMID: 30489164 DOI: 10.1080/02656736.2018.1539776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
525 Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Ziol M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, Zucman-Rossi J. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. J Hepatol 2021;74:1155-66. [PMID: 33338512 DOI: 10.1016/j.jhep.2020.11.052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
526 Chen P, Fang QX, Chen DB, Chen HS. Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(7): 673-683 [PMID: 34322196 DOI: 10.4251/wjgo.v13.i7.673] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
527 Li Y, Wu B, Sun R, Zhao M, Li N. miR-93-5p knockdown repressed hepatocellular carcinoma progression via increasing ERBB4 and TETs-dependent DNA demethylation. Autoimmunity 2021;:1-14. [PMID: 34435526 DOI: 10.1080/08916934.2021.1969552] [Reference Citation Analysis]
528 La Bella T, Imbeaud S, Peneau C, Mami I, Datta S, Bayard Q, Caruso S, Hirsch TZ, Calderaro J, Morcrette G, Guettier C, Paradis V, Amaddeo G, Laurent A, Possenti L, Chiche L, Bioulac-sage P, Blanc J, Letouze E, Nault J, Zucman-rossi J. Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut 2020;69:737-47. [DOI: 10.1136/gutjnl-2019-318281] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
529 Lu H, Gao L, Lv J. Circ_0078710 promotes the development of liver cancer by upregulating TXNDC5 via miR-431-5p. Ann Hepatol 2021;27:100551. [PMID: 34606982 DOI: 10.1016/j.aohep.2021.100551] [Reference Citation Analysis]
530 Lünse S, Heidecke C, Partecke LI; Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General Surgery, Visceral, Thoracic and Vascular Surgery, Universitätsmedizin Greifswald, Greifswald, Germany, Department of General, Visceral and Thoracic Surgery, Helios Klinikum Schleswig, Schleswig, Germany. Current Topics and Perspectives in Surgical Management of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 111-25. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch6] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
531 Yu J, Zhang C, Yu Q, Yu H, Zhang B. ADAR1 p110 Enhances Adhesion of Tumor Cells to Extracellular Matrix in Hepatocellular Carcinoma via Up-Regulating ITGA2 Expression. Med Sci Monit 2019;25:1469-79. [PMID: 30798327 DOI: 10.12659/MSM.911944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
532 Ren Y, Fan X, Chen G, Zhou D, Lin H, Cai X. Preoperative C-reactive protein/albumin ratio to predict mortality and recurrence of patients with hepatocellular carcinoma after curative resection.Med Clin (Barc). 2019;153:183-190. [PMID: 30606506 DOI: 10.1016/j.medcli.2018.11.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
533 Bresnahan E, Ramadori P, Heikenwalder M, Zender L, Lujambio A. Novel patient-derived preclinical models of liver cancer. J Hepatol 2020;72:239-49. [PMID: 31954489 DOI: 10.1016/j.jhep.2019.09.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
534 Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, Xue Z, Wang L, Beijersbergen RL, Qin W, Bernards R. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol 2018;69:1057-65. [PMID: 30030148 DOI: 10.1016/j.jhep.2018.07.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
535 Désert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S, Turlin B, Bellaud P, Perret C, Clément B, Lê Cao KA, Musso O. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017;66:1502-18. [PMID: 28498607 DOI: 10.1002/hep.29254] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
536 Zhang Y, Zeng F, Zeng M, Han X, Cai L, Zhang J, Weng J, Gao Y. Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model. Int J Biol Sci 2021;17:3554-72. [PMID: 34512165 DOI: 10.7150/ijbs.62168] [Reference Citation Analysis]
537 Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Dig Dis Sci. 2019;64:1016-1029. [PMID: 30887150 DOI: 10.1007/s10620-019-05582-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
538 Chen RX, Gan YH, Ge NL, Chen Y, Ma M, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG. A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. J Cancer 2019;10:6535-42. [PMID: 31777583 DOI: 10.7150/jca.34064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
539 Ferrandino G, Orf I, Smith R, Calcagno M, Thind AK, Debiram-Beecham I, Williams M, Gandelman O, de Saedeleer A, Kibble G, Lydon AM, Mayhew CA, Allsworth M, Boyle B, van der Schee MP, Allison M, Hoare M, Snowdon VK. Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound-Toward Improved Detection of Liver Impairment. Clin Transl Gastroenterol 2020;11:e00239. [PMID: 33094960 DOI: 10.14309/ctg.0000000000000239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
540 Yuan B, Liu J, Cao J, Yu Y, Zhang H, Wang F, Zhu Y, Xiao M, Liu S, Ye Y, Ma L, Xu D, Xu N, Li Y, Zhao B, Xu P, Jin J, Xu J, Chen X, Shen L, Lin X, Feng XH. PTPN3 acts as a tumor suppressor and boosts TGF-β signaling independent of its phosphatase activity. EMBO J 2019;38:e99945. [PMID: 31304624 DOI: 10.15252/embj.201899945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
541 Nozaki Y, Hikita H, Tanaka S, Fukumoto K, Urabe M, Sato K, Myojin Y, Doi A, Murai K, Sakane S, Saito Y, Kodama T, Sakamori R, Tatsumi T, Takehara T. Persistent hepatocyte apoptosis promotes tumorigenesis from diethylnitrosamine-transformed hepatocytes through increased oxidative stress, independent of compensatory liver regeneration. Sci Rep 2021;11:3363. [PMID: 33564095 DOI: 10.1038/s41598-021-83082-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
542 Wu T, Dong X, Yu D, Shen Z, Yu J, Yan S. Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway. Onco Targets Ther 2018;11:8633-42. [PMID: 30584322 DOI: 10.2147/OTT.S186186] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
543 Krasny L, Huang PH. Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. Mol Omics 2021;17:29-42. [PMID: 33034323 DOI: 10.1039/d0mo00072h] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
544 Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med. 2018;50:e416. [PMID: 29303512 DOI: 10.1038/emm.2017.165] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 21.7] [Reference Citation Analysis]
545 Song W, Zheng C, Liu M, Xu Y, Qian Y, Zhang Z, Su H, Li X, Wu H, Gong P, Li Y, Fan H. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p. Mol Ther 2021;29:2601-16. [PMID: 33839325 DOI: 10.1016/j.ymthe.2021.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
546 Cai J, Zhou M, Xu J. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma. World J Surg Oncol 2021;19:241. [PMID: 34389000 DOI: 10.1186/s12957-021-02354-8] [Reference Citation Analysis]
547 Sun Z, Lu Z, Li R, Shao W, Zheng Y, Shi X, Li Y, Song J. Construction of a Prognostic Model for Hepatocellular Carcinoma Based on Immunoautophagy-Related Genes and Tumor Microenvironment. Int J Gen Med 2021;14:5461-73. [PMID: 34526813 DOI: 10.2147/IJGM.S325884] [Reference Citation Analysis]
548 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Reference Citation Analysis]
549 Aramburu J, Antón R, Rivas A, Ramos JC, Larraona GS, Sangro B, Bilbao JI. Numerical zero-dimensional hepatic artery hemodynamics model for balloon-occluded transarterial chemoembolization. Int J Numer Method Biomed Eng 2018;34:e2983. [PMID: 29575739 DOI: 10.1002/cnm.2983] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
550 Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. Eur J Cancer 2017;87:101-12. [PMID: 29145036 DOI: 10.1016/j.ejca.2017.10.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
551 Maruta S, Ogasawara S, Ooka Y, Obu M, Inoue M, Itokawa N, Haga Y, Seki A, Okabe S, Azemoto R, Itobayashi E, Atsukawa M, Sugiura N, Mizumoto H, Koroki K, Kanayama K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 2020;9:382-396. [PMID: 32999866 DOI: 10.1159/000507022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
552 Xue C, Wang K, Jiang X, Gu C, Yu G, Zhong Y, Liu S, Nie Y, Zhou Y, Yang H. The Down-Regulation of SUZ12 Accelerates the Migration and Invasion of Liver Cancer Cells via Activating ERK1/2 Pathway. J Cancer 2019;10:1375-84. [PMID: 31031847 DOI: 10.7150/jca.29932] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
553 Qiu S, Zhong C, Zhao B, Li G, Wang J, Jehan S, Li J, Zhao X, Li D, Sui G. Transcriptome analysis of signaling pathways targeted by Ellagic acid in hepatocellular carcinoma cells. Biochim Biophys Acta Gen Subj 2021;1865:129911. [PMID: 33862123 DOI: 10.1016/j.bbagen.2021.129911] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
554 Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
555 Zhang T, Yang X, Xu W, Wang J, Wu D, Hong Z, Yuan S, Zeng Z, Jia X, Lu S, Safadi R, Han S, Yang Z, Neckers LM, Liangpunsakul S, Zhou W, Lu Y. Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy. Cancer Biol Med 2021:j. [PMID: 33764710 DOI: 10.20892/j.issn.2095-3941.2020.0262] [Reference Citation Analysis]
556 Jepsen P, Kraglund F, West J, Villadsen GE, Sørensen HT, Vilstrup H. Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis. J Hepatol 2020;73:1030-6. [PMID: 32512015 DOI: 10.1016/j.jhep.2020.05.043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
557 Zhao Z, Zhang D, Wu F, Tu J, Song J, Xu M, Ji J. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. J Cell Mol Med 2021;25:549-60. [PMID: 33210432 DOI: 10.1111/jcmm.16108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
558 Cao S, Liu M, Sehrawat TS, Shah VH. Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:630-47. [PMID: 33976393 DOI: 10.1038/s41575-021-00444-2] [Reference Citation Analysis]
559 Guo JC, Liu Z, Yang YJ, Guo M, Zhang JQ, Zheng JF. KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis. J Cell Mol Med 2021. [PMID: 33829656 DOI: 10.1111/jcmm.16342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
560 Liu G, Liu G, Cui X, Xu Y. Transcriptomic Data Analyses Reveal a Reprogramed Lipid Metabolism in HCV-Derived Hepatocellular Cancer. Front Cell Dev Biol 2020;8:581863. [PMID: 33195224 DOI: 10.3389/fcell.2020.581863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
561 Mittermeier C, Konopa A, Muehlich S. Molecular Mechanisms to Target Cellular Senescence in Hepatocellular Carcinoma. Cells 2020;9:E2540. [PMID: 33255630 DOI: 10.3390/cells9122540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
562 Cho K, Ro SW, Seo SH, Jeon Y, Moon H, Kim DY, Kim SU. Genetically Engineered Mouse Models for Liver Cancer. Cancers (Basel) 2019;12:E14. [PMID: 31861541 DOI: 10.3390/cancers12010014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
563 von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse AW, Riethdorf S, Wege H. Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. Oncotarget. 2017;8:89978-89987. [PMID: 29163804 DOI: 10.18632/oncotarget.21208] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
564 Benabou E, Salamé Z, Wendum D, Lequoy M, Tahraoui S, Merabtene F, Chrétien Y, Scatton O, Rosmorduc O, Fouassier L, Fartoux L, Praz F, Desbois-Mouthon C. Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features. Cancer Lett 2019;450:155-68. [PMID: 30849481 DOI: 10.1016/j.canlet.2019.02.037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
565 Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 2019; 25(19): 2279-2293 [PMID: 31148900 DOI: 10.3748/wjg.v25.i19.2279] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 23.5] [Reference Citation Analysis]
566 Rodríguez-Hernández MA, de la Cruz-Ojeda P, Gallego P, Navarro-Villarán E, Staňková P, Del Campo JA, Kučera O, Elkalaf M, Maseko TE, Červinková Z, Muntané J. Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells. Biochem Pharmacol 2020;176:113902. [PMID: 32156660 DOI: 10.1016/j.bcp.2020.113902] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
567 Lau WY, Lau SHY. The current role of radiofrequency ablation in the treatment of hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2017;16:122-6. [DOI: 10.1016/s1499-3872(16)60182-0] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
568 Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222-232. [PMID: 29379119 DOI: 10.1038/s41590-018-0044-z] [Cited by in Crossref: 281] [Cited by in F6Publishing: 289] [Article Influence: 93.7] [Reference Citation Analysis]
569 Wen L, Xin B, Wu P, Lin CH, Peng C, Wang G, Lee J, Lu LF, Feng GS. An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice. Hepatology 2019;69:2518-32. [PMID: 30693544 DOI: 10.1002/hep.30528] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
570 Xu C, Wu S, Schook LB, Schachtschneider KM. Translating Human Cancer Sequences Into Personalized Porcine Cancer Models. Front Oncol 2019;9:105. [PMID: 30873383 DOI: 10.3389/fonc.2019.00105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
571 Marzio A, Pagano M. Loss of the deubiquitinase OTULIN promotes hepatocellular carcinoma (HCC) in an mTOR-dependent manner. Cell Death Differ 2020;27:1455-6. [PMID: 32225171 DOI: 10.1038/s41418-020-0531-2] [Reference Citation Analysis]
572 Cai Y, Xia J, Wang N, Zhou H. Identification of prognostic alternative splicing signatures in hepatitis B or/and C viruses related hepatocellular carcinoma. Genomics 2020;112:3396-406. [PMID: 32525024 DOI: 10.1016/j.ygeno.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
573 Fa B, Luo C, Tang Z, Yan Y, Zhang Y, Yu Z. Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma. EBioMedicine. 2019;44:250-260. [PMID: 31101593 DOI: 10.1016/j.ebiom.2019.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
574 Fondevila F, Méndez-Blanco C, Fernández-Palanca P, González-Gallego J, Mauriz JL. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp Mol Med 2019;51:1-15. [PMID: 31551425 DOI: 10.1038/s12276-019-0308-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
575 Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, von Felden J, Martins-Filho SN, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018;37:3740-52. [PMID: 29628508 DOI: 10.1038/s41388-018-0206-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
576 Horvat N, Araujo-Filho JAB, Assuncao-Jr AN, Machado FAM, Sims JA, Rocha CCT, Oliveira BC, Horvat JV, Maccali C, Puga ALBL, Chagas AL, Menezes MR, Cerri GG. Radiomic analysis of MRI to Predict Sustained Complete Response after Radiofrequency Ablation in Patients with Hepatocellular Carcinoma - A Pilot Study. Clinics (Sao Paulo) 2021;76:e2888. [PMID: 34287480 DOI: 10.6061/clinics/2021/e2888] [Reference Citation Analysis]
577 Rapposelli IG, Tada T, Shimose S, Burgio V, Kumada T, Iwamoto H, Hiraoka A, Niizeki T, Atsukawa M, Koga H, Hirooka M, Torimura T, Iavarone M, Tortora R, Campani C, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Giuseppe Foschi F, Silletta M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Tanaka T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Rimini M, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver Int 2021. [PMID: 34250737 DOI: 10.1111/liv.15014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
578 Dang H, Pomyen Y, Martin SP, Dominguez DA, Yim SY, Lee JS, Budhu A, Shah AP, Bodzin AS, Wang XW. NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma. Sci Rep 2019;9:3369. [PMID: 30833661 DOI: 10.1038/s41598-019-39727-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
579 Yishake D, He TT, Liu ZY, Chen S, Luo Y, Liu XZ, Huang RZ, Lan QY, Fang AP, Zhu HL. Dietary protein and prognosis of hepatocellular carcinoma: a prospective cohort study. Food Funct 2021;12:11568-76. [PMID: 34709274 DOI: 10.1039/d1fo02013g] [Reference Citation Analysis]
580 Borowa-Mazgaj B, de Conti A, Tryndyak V, Steward CR, Jimenez L, Melnyk S, Seneshaw M, Mirshahi F, Rusyn I, Beland FA, Sanyal AJ, Pogribny IP. Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis. Toxicol Sci 2019;170:273-82. [PMID: 31086990 DOI: 10.1093/toxsci/kfz110] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
581 Zeng J, Zeng J, Liu J, Zeng J. Development of pre and post-operative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma. Liver Int 2021. [PMID: 34416088 DOI: 10.1111/liv.15042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
582 Albadawi H, Zhang Z, Altun I, Hu J, Jamal L, Ibsen KN, Tanner EEL, Mitragotri S, Oklu R. Percutaneous liquid ablation agent for tumor treatment and drug delivery. Sci Transl Med 2021;13:eabe3889. [PMID: 33568519 DOI: 10.1126/scitranslmed.abe3889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
583 Ding W, Tan Y, Qian Y, Xue W, Wang Y, Jiang P, Xu X. Clinicopathologic and prognostic significance of tumor-associated macrophages in patients with hepatocellular carcinoma: A meta-analysis. PLoS One 2019;14:e0223971. [PMID: 31618252 DOI: 10.1371/journal.pone.0223971] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
584 Wong MM, Chan HY, Aziz NA, Ramasamy TS, Bong JJ, Ch'ng ES, Armon S, Peh SC, Teow SY. Interplay of autophagy and cancer stem cells in hepatocellular carcinoma. Mol Biol Rep 2021;48:3695-717. [PMID: 33893928 DOI: 10.1007/s11033-021-06334-9] [Reference Citation Analysis]
585 Saillard C, Schmauch B, Laifa O, Moarii M, Toldo S, Zaslavskiy M, Pronier E, Laurent A, Amaddeo G, Regnault H, Sommacale D, Ziol M, Pawlotsky JM, Mulé S, Luciani A, Wainrib G, Clozel T, Courtiol P, Calderaro J. Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides. Hepatology 2020;72:2000-13. [PMID: 32108950 DOI: 10.1002/hep.31207] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 32.0] [Reference Citation Analysis]
586 Xu X, Lei Y, Zhou H, Guo Y, Liu H, Jiang J, Yang Y, Wu B. β-Arrestin1 is involved in hepatocellular carcinoma metastasis via extracellular signal-regulated kinase-mediated epithelial-mesenchymal transition. J Gastroenterol Hepatol 2020;35:2229-40. [PMID: 32445259 DOI: 10.1111/jgh.15115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
587 Liu Z, Mao X, Jiang Y, Cai N, Jin L, Zhang T, Chen X. Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China. Cancer Med 2019;8:5787-99. [PMID: 31385465 DOI: 10.1002/cam4.2477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
588 Deng M, Fang L, Li SH, Zhao RC, Mei J, Zou JW, Wei W, Guo RP. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma. Mutagenesis 2021;36:369-79. [PMID: 34467992 DOI: 10.1093/mutage/geab032] [Reference Citation Analysis]
589 Seino S, Tsuchiya A, Watanabe Y, Kawata Y, Kojima Y, Ikarashi S, Yanai H, Nakamura K, Kumaki D, Hirano M, Funakoshi K, Aono T, Sakai T, Sakata J, Takamura M, Kawai H, Yamagiwa S, Wakai T, Terai S. Clinical outcome of hepatocellular carcinoma can be predicted by the expression of hepatic progenitor cell markers and serum tumour markers. Oncotarget 2018;9:21844-60. [PMID: 29774107 DOI: 10.18632/oncotarget.25074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
590 Seehawer M, D'Artista L, Zender L. The Worst from Both Worlds: cHCC-ICC. Cancer Cell 2019;35:823-4. [PMID: 31185207 DOI: 10.1016/j.ccell.2019.05.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
591 Hazari Y, Bravo-San Pedro JM, Hetz C, Galluzzi L, Kroemer G. Autophagy in hepatic adaptation to stress. J Hepatol. 2020;72:183-196. [PMID: 31849347 DOI: 10.1016/j.jhep.2019.08.026] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 47.0] [Reference Citation Analysis]
592 Rekik S, Allaire M, Mumana A, Guyot E, Nkontchou G, Grando V, Blaise L, Ziol M, Nahon P, Ganne‐carrié N, Sutter O, Seror O, Nault J. Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis. Journal of Gastroenterology and Hepatology 2019;35:142-50. [DOI: 10.1111/jgh.14763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
593 Pineau P, Ruiz E, Deharo E, Bertani S. On hepatocellular carcinoma in South America and early-age onset of the disease. Clin Res Hepatol Gastroenterol 2019;43:522-6. [PMID: 30482474 DOI: 10.1016/j.clinre.2018.10.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
594 Lu L, Daigle BJ Jr. Prognostic analysis of histopathological images using pre-trained convolutional neural networks: application to hepatocellular carcinoma. PeerJ 2020;8:e8668. [PMID: 32201640 DOI: 10.7717/peerj.8668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
595 Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372. [PMID: 28893941 DOI: 10.1098/rstb.2016.0274] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 33.3] [Reference Citation Analysis]
596 Xue D, Han J, Liu Y, Tuo H, Peng Y. Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review). Cancer Biol Ther 2021;22:279-90. [PMID: 33847207 DOI: 10.1080/15384047.2021.1898728] [Reference Citation Analysis]
597 Dimitrakopoulos C, Hindupur SK, Colombi M, Liko D, Ng CKY, Piscuoglio S, Behr J, Moore AL, Singer J, Ruscheweyh HJ, Matter MS, Mossmann D, Terracciano LM, Hall MN, Beerenwinkel N. Multi-omics data integration reveals novel drug targets in hepatocellular carcinoma. BMC Genomics 2021;22:592. [PMID: 34348664 DOI: 10.1186/s12864-021-07876-9] [Reference Citation Analysis]
598 Sia D, Llovet JM. Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2017;14:571-2. [PMID: 28765583 DOI: 10.1038/nrgastro.2017.103] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
599 Lee SE, Alcedo KP, Kim HJ, Snider NT. Alternative Splicing in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2020;10:699-712. [PMID: 32389640 DOI: 10.1016/j.jcmgh.2020.04.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
600 Liu G, Ouyang X, Gong L, Yao L, Liu S, Li J, Zhang Q, Xiao Y. E2F3 promotes liver cancer progression under the regulation of circ-PRKAR1B. Mol Ther Nucleic Acids 2021;26:104-13. [PMID: 34513297 DOI: 10.1016/j.omtn.2021.07.002] [Reference Citation Analysis]
601 Unfried JP, Sangro P, Prats-Mari L, Sangro B, Fortes P. The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers (Basel) 2021;13:2651. [PMID: 34071216 DOI: 10.3390/cancers13112651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
602 Zhang P, Feng J, Wu X, Chu W, Zhang Y, Li P. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases. Pathol Oncol Res 2021;27:588532. [PMID: 34257537 DOI: 10.3389/pore.2021.588532] [Reference Citation Analysis]
603 D'Avola D, Bilbao JI, Sangro B. Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. Cardiovasc Intervent Radiol 2019;42:1262-70. [PMID: 31069465 DOI: 10.1007/s00270-019-02221-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
604 Tao J, Krutsenko Y, Moghe A, Singh S, Poddar M, Bell A, Oertel M, Singhi AD, Geller D, Chen X, Lujambio A, Liu S, Monga SP. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications. Hepatology 2021;74:741-59. [PMID: 33529367 DOI: 10.1002/hep.31730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
605 Ndiaye H, Liu JY, Hall A, Minogue S, Morgan MY, Waugh MG. Immunohistochemical staining reveals differential expression of ACSL3 and ACSL4 in hepatocellular carcinoma and hepatic gastrointestinal metastases. Biosci Rep 2020;40:BSR20200219. [PMID: 32286604 DOI: 10.1042/BSR20200219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
606 Yang Z, Zhu H, Zhang L, Wei Q, Zhou L, Xu X, Song P, Liu J, Xie H, Zheng S. DNA methylation of SOCS1/2/3 predicts hepatocellular carcinoma recurrence after liver transplantation. Mol Biol Rep 2020;47:1773-82. [PMID: 32006198 DOI: 10.1007/s11033-020-05271-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
607 Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers (Basel) 2020;12:E1668. [PMID: 32585931 DOI: 10.3390/cancers12061668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
608 Atwa SM, Odenthal M, M El Tayebi H. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4343. [PMID: 34503153 DOI: 10.3390/cancers13174343] [Reference Citation Analysis]
609 Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncology 2020;16:2587-9. [DOI: 10.2217/fon-2020-0669] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
610 Setten RL, Lightfoot HL, Habib NA, Rossi JJ. Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma. Curr Pharm Biotechnol 2018;19:611-21. [PMID: 29886828 DOI: 10.2174/1389201019666180611093428] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
611 Xu Q, Wang Y, Huang W. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. Int Immunopharmacol 2021;92:107333. [PMID: 33486322 DOI: 10.1016/j.intimp.2020.107333] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
612 Xie Q, Chi S, Fang Y, Sun Y, Meng L, Ding J, Chen Y. PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma. Signal Transduct Target Ther 2021;6:130. [PMID: 33785733 DOI: 10.1038/s41392-021-00522-6] [Reference Citation Analysis]
613 Mehrabi M, Amini F, Mehrabi S. Kill and Clearance in HCC: An Approach Based on NK Cells and Macrophages. Front Oncol 2021;11:693076. [PMID: 34557407 DOI: 10.3389/fonc.2021.693076] [Reference Citation Analysis]
614 Cherng YG, Chu YC, Yadav VK, Huang TY, Hsieh MS, Lee KF, Lee WH, Yeh CT, Ong JR. Induced Mitochondrial Alteration and DNA Damage via IFNGR-JAK2-STAT1-PARP1 Pathway Facilitates Viral Hepatitis Associated Hepatocellular Carcinoma Aggressiveness and Stemness. Cancers (Basel) 2021;13:2755. [PMID: 34199353 DOI: 10.3390/cancers13112755] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
615 Ashhab AA, Rodin H, Powell J, Debes JD. Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA. Eur J Gastroenterol Hepatol 2019;31:24-8. [PMID: 30024491 DOI: 10.1097/MEG.0000000000001212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
616 Kamimura K. Identification of molecular transition of hepatocellular carcinoma: a novel method to predict the initiation of metastasis. Stem Cell Investig 2019;6:5. [PMID: 30976602 DOI: 10.21037/sci.2019.02.02] [Reference Citation Analysis]
617 Zhao F, Liu A, Gong X, Chen H, Wei J, Chen B, Chen S, Yang R, Fan Y, Mao R. Hypoxia-induced RNASEH2A limits activation of cGAS-STING signaling in HCC and predicts poor prognosis. Tumori 2021;:3008916211026019. [PMID: 34165025 DOI: 10.1177/03008916211026019] [Reference Citation Analysis]
618 Wu J, Chen Y, Zuo C, Kuang N, Li R, Li Q, Ruan J, Cui E, Xu R, Yu J. A novel index for staging hepatitis B related liver cirrhosis in patients with hepatocellular carcinoma. Sci Prog 2021;104:368504211018052. [PMID: 34003700 DOI: 10.1177/00368504211018052] [Reference Citation Analysis]
619 Pikarsky E. Neighbourhood deaths cause a switch in cancer subtype. Nature 2018;562:45-6. [PMID: 30275548 DOI: 10.1038/d41586-018-06217-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
620 Sohn W, Lee HW, Lee S, Lim JH, Lee MW, Park CH, Yoon SK. Obesity and the risk of primary liver cancer: A systematic review and meta-analysis. Clin Mol Hepatol 2021;27:157-74. [PMID: 33238333 DOI: 10.3350/cmh.2020.0176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
621 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
622 Lombardo D, Saitta C, Giosa D, Di Tocco FC, Musolino C, Caminiti G, Chines V, Franzè MS, Alibrandi A, Navarra G, Raimondo G, Pollicino T. Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy. Oncol Lett 2020;19:2368-74. [PMID: 32194736 DOI: 10.3892/ol.2020.11332] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
623 Wang H, Du PC, Wu MC, Cong WM. Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. Hepatobiliary Surg Nutr. 2018;7:418-428. [PMID: 30652086 DOI: 10.21037/hbsn.2018.09.05] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
624 Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology 2019;70:1262-77. [DOI: 10.1016/j.jhep.2019.01.028] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 29.5] [Reference Citation Analysis]
625 Si A, Wang L, Miao K, Zhang R, Ji H, Lei Z, Cheng Z, Fang X, Hao B. miR-219 regulates liver cancer stem cell expansion via E-cadherin pathway. Cell Cycle 2019;18:3550-61. [PMID: 31724462 DOI: 10.1080/15384101.2019.1691762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
626 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
627 Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W, du Chatinier A, Wang L, Gao D, Evers B, Jin G, Xue Z, Schepers A, Jochems F, Sanchez AM, Mainardi S, Te Riele H, Beijersbergen RL, Qin W, Akkari L, Bernards R. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 2019;574:268-72. [PMID: 31578521 DOI: 10.1038/s41586-019-1607-3] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 41.0] [Reference Citation Analysis]
628 Ueshima K, Ogasawara S, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura T, Kuroda H, Ohki T, Nagashima K, Ooka Y, Takita M, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M. Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2020;9:583-95. [PMID: 33083282 DOI: 10.1159/000508724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
629 Renzulli M, Tovoli F, Clemente A, Ierardi AM, Pettinari I, Peta G, Marasco G, Festi D, Piscaglia F, Cappabianca S, Carrafiello G, Golfieri R. Ablation for hepatocellular carcinoma: beyond the standard indications. Med Oncol 2020;37:23. [PMID: 32166482 DOI: 10.1007/s12032-020-01348-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
630 Giovannini C, Fornari F, Dallo R, Gagliardi M, Nipoti E, Vasuri F, Coadă CA, Ravaioli M, Bolondi L, Gramantieri L. MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. Acta Histochem 2018;120:95-102. [PMID: 29249451 DOI: 10.1016/j.acthis.2017.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
631 Turato C, Fornari F, Pollutri D, Fassan M, Quarta S, Villano G, Ruvoletto M, Bolondi L, Gramantieri L, Pontisso P. MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. J Clin Med. 2019;8. [PMID: 30717317 DOI: 10.3390/jcm8020171] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
632 Xing J, Bhuria V, Bui KC, Nguyen MLT, Hu Z, Hsieh CJ, Wittstein K, Stadler M, Wilkens L, Li J, Kalesse M, Bozko P, Plentz RR. Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition. Cancers (Basel) 2020;12:E615. [PMID: 32155915 DOI: 10.3390/cancers12030615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
633 Dai T, Deng M, Ye L, Lin G, Liu R, Deng Y, Li R, Liu W, Li H, Yang Y, Chen G, Wang G. Nomograms based on clinicopathological factors and inflammatory indicators for prediction of early and late recurrence of hepatocellular carcinoma after surgical resection for patients with chronic hepatitis B.Ann Transl Med. 2021;9:12. [PMID: 33553305 DOI: 10.21037/atm-20-1353] [Reference Citation Analysis]
634 Hou D, Xiong J, Li Y, Peng Y, Xiong L. Efficacy and safety of Xiaoaiping injection for liver cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21993. [PMID: 32871951 DOI: 10.1097/MD.0000000000021993] [Reference Citation Analysis]
635 Wu C, Qi X, Qiu Z, Deng G, Zhong L. Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC. Aging (Albany NY) 2021;13:22148-63. [PMID: 34491228 DOI: 10.18632/aging.203494] [Reference Citation Analysis]
636 Yue D, Sun X. Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma. Cell Death Dis 2018;9:935. [PMID: 30224718 DOI: 10.1038/s41419-018-0960-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
637 Haider C, Hnat J, Wagner R, Huber H, Timelthaler G, Grubinger M, Coulouarn C, Schreiner W, Schlangen K, Sieghart W, Peck-Radosavljevic M, Mikulits W. Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma. Hepatology 2019;69:222-36. [PMID: 30014484 DOI: 10.1002/hep.30166] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
638 Koroki K, Kanogawa N, Maruta S, Ogasawara S, Iino Y, Obu M, Okubo T, Itokawa N, Maeda T, Inoue M, Haga Y, Seki A, Okabe S, Koma Y, Azemoto R, Atsukawa M, Itobayashi E, Ito K, Sugiura N, Mizumoto H, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Saito T, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kato N. Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2021;10:473-84. [PMID: 34721509 DOI: 10.1159/000515552] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
639 Yu Q, Xiang L, Chen Z, Liu X, Ou H, Zhou J, Yang D. MALAT1 functions as a competing endogenous RNA to regulate SMAD5 expression by acting as a sponge for miR-142-3p in hepatocellular carcinoma. Cell Biosci 2019;9:39. [PMID: 31168355 DOI: 10.1186/s13578-019-0299-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
640 Chaudhary K, Poirion OB, Lu L, Huang S, Ching T, Garmire LX. Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes. Clin Cancer Res 2019;25:463-72. [PMID: 30242023 DOI: 10.1158/1078-0432.CCR-18-0088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
641 Harvey JB, Phan LH, Villarreal OE, Bowser JL. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol 2020;11:508. [PMID: 32351498 DOI: 10.3389/fimmu.2020.00508] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
642 Yang G, Xu Q, Wan Y, Zhang L, Wang L, Meng F. Circ-CSPP1 knockdown suppresses hepatocellular carcinoma progression through miR-493-5p releasing-mediated HMGB1 downregulation. Cell Signal 2021;86:110065. [PMID: 34182091 DOI: 10.1016/j.cellsig.2021.110065] [Reference Citation Analysis]
643 Dolicka D, Sobolewski C, Correia de Sousa M, Gjorgjieva M, Foti M. mRNA Post-Transcriptional Regulation by AU-Rich Element-Binding Proteins in Liver Inflammation and Cancer. Int J Mol Sci 2020;21:E6648. [PMID: 32932781 DOI: 10.3390/ijms21186648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
644 Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, Weitz DA, Sequist LV, Ryan DP, Chung RT, Zhu AX, Isselbacher KJ, Ting DT, Toner M, Maheswaran S, Haber DA. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci USA. 2017;114:1123-1128. [PMID: 28096363 DOI: 10.1073/pnas.1617032114] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 21.5] [Reference Citation Analysis]
645 Danos D, Leonardi C, Gilliland A, Shankar S, Srivastava RK, Simonsen N, Ferguson T, Yu Q, Wu XC, Scribner R. Increased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated Disadvantage. Front Oncol 2018;8:375. [PMID: 30254987 DOI: 10.3389/fonc.2018.00375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
646 Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019; 25(25): 3151-3167 [PMID: 31333308 DOI: 10.3748/wjg.v25.i25.3151] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
647 Gu X, Chu Q, Zheng Q, Wang J, Zhu H. The dual functions of the long noncoding RNA CASC15 in malignancy. Biomed Pharmacother 2021;135:111212. [PMID: 33433353 DOI: 10.1016/j.biopha.2020.111212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
648 Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun 2021;27:100328. [PMID: 33549983 DOI: 10.1016/j.ctarc.2021.100328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
649 Molina-sánchez P, Lujambio A. Experimental Models for Preclinical Research in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 333-58. [DOI: 10.1007/978-3-030-21540-8_16] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
650 Korhan P, Yılmaz Y, Bağırsakçı E, Güneş A, Topel H, Carr BI, Atabey N. Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:7568742. [PMID: 30425976 DOI: 10.1155/2018/7568742] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
651 Weidle UH, Schmid D, Birzele F, Brinkmann U. MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. Cancer Genomics Proteomics 2020;17:1-21. [PMID: 31882547 DOI: 10.21873/cgp.20163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
652 Yang Y, Sun M, Yao W, Wang F, Li X, Wang W, Li J, Gao Z, Qiu L, You R, Yang C, Ba Q, Wang H. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J Immunother Cancer 2020;8:e000317. [PMID: 32179631 DOI: 10.1136/jitc-2019-000317] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
653 Henderson JM, Polak N, Chen J, Roediger B, Weninger W, Kench JG, McCaughan GW, Zhang HE, Gorrell MD. Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma. Sci Rep. 2018;8:10283. [PMID: 29980757 DOI: 10.1038/s41598-018-28486-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
654 Li Y, Zhang J, Gu J, Hu K, Huang S, Conti PS, Wu H, Chen K. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma. Mol Imaging Biol 2020;22:134-43. [PMID: 31044341 DOI: 10.1007/s11307-019-01356-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
655 Wang HY, Zhang B, Zhou JN, Wang DX, Xu YC, Zeng Q, Jia YL, Xi JF, Nan X, He LJ, Yue W, Pei XT. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex. Cell Death Dis 2019;10:453. [PMID: 31186405 DOI: 10.1038/s41419-019-1676-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
656 An T, Dong T, Zhou H, Chen Y, Zhang J, Zhang Y, Li Z, Yang X. The transcription factor Krüppel-like factor 5 promotes cell growth and metastasis via activating PI3K/AKT/Snail signaling in hepatocellular carcinoma. Biochem Biophys Res Commun 2019;508:159-68. [PMID: 30473218 DOI: 10.1016/j.bbrc.2018.11.084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
657 Zhang S, Liu J, Zhu J, Xiao M, Lu C, Ni R, Qu L. Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis. Japanese Journal of Clinical Oncology 2019;49:646-55. [DOI: 10.1093/jjco/hyz046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
658 Yang P, Huang X, Lai C, Li L, Li T, Huang P, Ouyang S, Yan J, Cheng S, Lei G, Wang Z, Yu L, Hong Z, Li R, Dong H, Wang C, Yu Y, Wang X, Li X, Wang L, Lv F, Yin Y, Yang H, Song J, Gao Q, Wang X, Zhang S. SET domain containing 1B gene is mutated in primary hepatic neuroendocrine tumors. Int J Cancer 2019;145:2986-95. [PMID: 30977120 DOI: 10.1002/ijc.32334] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
659 Xu L, Zhang M, Zheng X, Yi P, Lan C, Xu M. The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143:17-27. [PMID: 27614453 DOI: 10.1007/s00432-016-2256-7] [Cited by in Crossref: 180] [Cited by in F6Publishing: 197] [Article Influence: 36.0] [Reference Citation Analysis]
660 Li Y, Wang R, Xiong S, Wang X, Zhao Z, Bai S, Wang Y, Zhao Y, Cheng B. Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling. J Mol Med (Berl) 2019;97:243-55. [PMID: 30564864 DOI: 10.1007/s00109-018-1731-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
661 Bo C, Li N, He L, Zhang S, An Y. Long non-coding RNA ILF3-AS1 facilitates hepatocellular carcinoma progression by stabilizing ILF3 mRNA in an m6A-dependent manner. Hum Cell 2021;34:1843-54. [PMID: 34491544 DOI: 10.1007/s13577-021-00608-x] [Reference Citation Analysis]
662 Shi WK, Zhu XD, Wang CH, Zhang YY, Cai H, Li XL, Cao MQ, Zhang SZ, Li KS, Sun HC. PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT. Cell Death Dis 2018;9:428. [PMID: 29559632 DOI: 10.1038/s41419-018-0435-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
663 Li Z, Zhang H, Han J, Chen Y, Lin H, Yang T. Surface Nanopore Engineering of 2D MXenes for Targeted and Synergistic Multitherapies of Hepatocellular Carcinoma. Adv Mater 2018;30:e1706981. [PMID: 29663543 DOI: 10.1002/adma.201706981] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 25.3] [Reference Citation Analysis]
664 Ji B, Cai H, Yang Y, Peng F, Song M, Sun K, Yan F, Liu Y. Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. Acta Biomaterialia 2020;111:363-72. [DOI: 10.1016/j.actbio.2020.04.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
665 Zhang YP, Bao ZW, Wu JB, Chen YH, Chen JR, Xie HY, Zhou L, Wu J, Zheng SS. Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy. Technol Cancer Res Treat 2020;19:1533033820944274. [PMID: 32715976 DOI: 10.1177/1533033820944274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
666 Gao Y, Gu J, Wang Y, Fu D, Zhang W, Zheng G, Wang X. Hepatitis B virus X protein boosts hepatocellular carcinoma progression by downregulating microRNA-137. Pathol Res Pract 2020;216:152981. [PMID: 32527447 DOI: 10.1016/j.prp.2020.152981] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
667 Gu X, Zhou H, Chu Q, Zheng Q, Wang J, Zhu H. Uncovering the Association Between m5C Regulator-Mediated Methylation Modification Patterns and Tumour Microenvironment Infiltration Characteristics in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:727935. [PMID: 34589490 DOI: 10.3389/fcell.2021.727935] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
668 Li H, Han G, Li X, Li B, Wu B, Jin H, Wu L, Wang W. MAPK-RAP1A Signaling Enriched in Hepatocellular Carcinoma Is Associated With Favorable Tumor-Infiltrating Immune Cells and Clinical Prognosis. Front Oncol 2021;11:649980. [PMID: 34178637 DOI: 10.3389/fonc.2021.649980] [Reference Citation Analysis]
669 Takaya H, Namisaki T, Kitade M, Shimozato N, Kaji K, Tsuji Y, Nakanishi K, Noguchi R, Fujinaga Y, Sawada Y, Saikawa S, Sato S, Kawaratani H, Moriya K, Akahane T, Yoshiji H. Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. World J Gastrointest Oncol 2019; 11(10): 887-897 [PMID: 31662827 DOI: 10.4251/wjgo.v11.i10.887] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
670 Labgaa I, Tabrizian P, Titano J, Kim E, Thung SN, Florman S, Schwartz M, Melloul E. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. HPB 2019;21:1497-504. [DOI: 10.1016/j.hpb.2019.03.360] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
671 Wu C, Chen W, Fang M, Boye A, Tao X, Xu Y, Hou S, Yang Y. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocellular carcinoma progression via miR-145/miR-21 mediated Smad3 phosphorylation. Journal of Ethnopharmacology 2019;231:98-112. [DOI: 10.1016/j.jep.2018.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
672 Gao Y, Li Z, Hong Y, Li T, Hu X, Sun L, Chen Z, Chen Z, Luo Z, Wang X, Kong J, Li G, Wang H, Leo HL, Yu H, Xi L, Guo Q. Decellularized liver as a translucent ex vivo model for vascular embolization evaluation. Biomaterials 2020;240:119855. [DOI: 10.1016/j.biomaterials.2020.119855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
673 Zhou B, Xiong Z, Wang P, Peng C, Shen M, Shi X. Acetylated Polyethylenimine-Entrapped Gold Nanoparticles Enable Negative Computed Tomography Imaging of Orthotopic Hepatic Carcinoma. Langmuir 2018;34:8701-7. [DOI: 10.1021/acs.langmuir.8b01669] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
674 Livingstone MC, Johnson NM, Roebuck BD, Kensler TW, Groopman JD. Serum miR-182 is a predictive biomarker for dichotomization of risk of hepatocellular carcinoma in rats. Mol Carcinog. 2019;58:2017-2025. [PMID: 31373075 DOI: 10.1002/mc.23093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
675 Zhang HE, Henderson JM, Gorrell MD. Animal models for hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis 2019;1865:993-1002. [PMID: 31007176 DOI: 10.1016/j.bbadis.2018.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
676 Martín-Sierra C, Colombo S, Martins R, Laranjeira P, Melo T, Abrantes AM, Oliveira RC, Tralhão JG, Botelho MF, Furtado E, Domingues P, Domingues MR, Paiva A. Tumor Resection Induces Alterations on Serum Phospholipidome of Liver Cancer Patients. Lipids 2020;55:185-91. [PMID: 32045496 DOI: 10.1002/lipd.12221] [Reference Citation Analysis]
677 Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017;66:952-61. [PMID: 28126467 DOI: 10.1016/j.jhep.2017.01.010] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 17.5] [Reference Citation Analysis]
678 Jovel J, Lin Z, O'keefe S, Willows S, Wang W, Zhang G, Patterson J, Moctezuma-Velázquez C, Kelvin DJ, Ka-Shu Wong G, Mason AL. A Survey of Molecular Heterogeneity in Hepatocellular Carcinoma. Hepatol Commun 2018;2:941-55. [PMID: 30094405 DOI: 10.1002/hep4.1197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
679 Sharma A, Kim E, Mun S, Ji MS, Chung BG, Kim JS. Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma. Dyes and Pigments 2019;163:628-33. [DOI: 10.1016/j.dyepig.2018.12.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
680 Zhang L, Ding J, Li HY, Wang ZH, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta Rev Cancer 2020;1874:188441. [PMID: 33007432 DOI: 10.1016/j.bbcan.2020.188441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
681 Ren X, Dong Y, Duan M, Zhang H, Gao P. Abnormal expression of HNRNPA3 in multistep hepatocarcinogenesis. Oncol Lett 2021;21:46. [PMID: 33281957 DOI: 10.3892/ol.2020.12307] [Reference Citation Analysis]
682 Hao F, Fei X, Ren X, Xi Xiao J, Chen Y, Wang J. Pseudogene AKR1B10P1 enhances tumorigenicity and regulates epithelial-mesenchymal transition in hepatocellular carcinoma via stabilizing SOX4. J Cell Mol Med 2020;24:11779-90. [PMID: 32924268 DOI: 10.1111/jcmm.15790] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
683 Nejabat M, Riegler T, Reitinger T, Subosits S, Römer M, Eichner J, Bilban M, Zell A, Huber WW, Schulte-Hermann R, Grasl-Kraupp B. Mesenchyme-derived factors enhance preneoplastic growth by non-genotoxic carcinogens in rat liver. Arch Toxicol 2018;92:953-66. [PMID: 29270806 DOI: 10.1007/s00204-017-2080-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
684 Han L, Jia L, Zan Y. Long intergenic noncoding RNA smad7 (Linc-smad7) promotes the epithelial-mesenchymal transition of HCC by targeting the miR-125b/SIRT6 axis. Cancer Med 2020;9:9123-37. [PMID: 33037850 DOI: 10.1002/cam4.3515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
685 Callegari E, D'Abundo L, Guerriero P, Simioni C, Elamin BK, Russo M, Cani A, Bassi C, Zagatti B, Giacomelli L, Blandamura S, Moshiri F, Ultimo S, Frassoldati A, Altavilla G, Gramantieri L, Neri LM, Sabbioni S, Negrini M. miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Mol Ther Nucleic Acids 2018;11:485-93. [PMID: 29858083 DOI: 10.1016/j.omtn.2018.04.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 14.7] [Reference Citation Analysis]
686 Zhang G, Li X, Chen Q, Li J, Ruan Q, Chen YH, Yang X, Wan X. CD317 Activates EGFR by Regulating Its Association with Lipid Rafts. Cancer Res 2019;79:2220-31. [PMID: 30890618 DOI: 10.1158/0008-5472.CAN-18-2603] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
687 Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
688 Wang J, Meng J, Ran W, Lee RJ, Teng L, Zhang P, Li Y. Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein. Nano Lett 2019;19:5266-76. [PMID: 31361965 DOI: 10.1021/acs.nanolett.9b01717] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
689 Zheng W, Yao M, Qian Q, Sai W, Qiu L, Yang J, Wu W, Dong Z, Yao D. Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. Oncotarget 2017;8:52321-32. [PMID: 28881732 DOI: 10.18632/oncotarget.13674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
690 Kaffe E, Magkrioti C, Aidinis V. Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer. Cancers (Basel) 2019;11:E1626. [PMID: 31652837 DOI: 10.3390/cancers11111626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
691 Dauki AM, Blachly JS, Kautto EA, Ezzat S, Abdel-Rahman MH, Coss CC. Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression. Cancer Res 2020;80:561-75. [PMID: 31685543 DOI: 10.1158/0008-5472.CAN-19-1117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
692 Cui H, Dai G, Guan J. Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World. Onco Targets Ther 2020;13:143-9. [PMID: 32021262 DOI: 10.2147/OTT.S234868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
693 Hu J, Wu W, Qin Y, Liu C, Wei P, Hu J, Seeberger PH, Yin J. Fabrication of Glyco‐Metal‐Organic Frameworks for Targeted Interventional Photodynamic/Chemotherapy for Hepatocellular Carcinoma through Percutaneous Transperitoneal Puncture. Adv Funct Mater 2020;30:1910084. [DOI: 10.1002/adfm.201910084] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
694 Kudo M. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer 2018;7:1-19. [PMID: 29662829 DOI: 10.1159/000487148] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 13.7] [Reference Citation Analysis]
695 Wang Z, Zhu J, Liu Y, Liu C, Wang W, Chen F, Ma L. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. J Transl Med 2020;18:67. [PMID: 32046766 DOI: 10.1186/s12967-020-02255-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 21.0] [Reference Citation Analysis]
696 Fu Y, Urban DJ, Nani RR, Zhang YF, Li N, Fu H, Shah H, Gorka AP, Guha R, Chen L, Hall MD, Schnermann MJ, Ho M. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology 2019;70:563-76. [PMID: 30353932 DOI: 10.1002/hep.30326] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
697 Wirtz TH, Brandt EF, Berres ML. Liver DCs in health and disease. Int Rev Cell Mol Biol 2019;348:263-99. [PMID: 31810555 DOI: 10.1016/bs.ircmb.2019.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
698 Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS One 2019;14:e0219469. [PMID: 31291332 DOI: 10.1371/journal.pone.0219469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
699 Hu X, Zhao Y, Wei L, Zhu B, Song D, Wang J, Yu L, Wu J. CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis. Oncogene 2017;36:4047-59. [DOI: 10.1038/onc.2017.10] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
700 Takahashi S, Tanaka N, Fukami T, Xie C, Yagai T, Kim D, Velenosi TJ, Yan T, Krausz KW, Levi M, Gonzalez FJ. Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development. Hepatol Commun. 2018;2:1567-1582. [PMID: 30556042 DOI: 10.1002/hep4.1263] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
701 Eferl R, Trauner M. Chromosomal instability in HCC: a key function for checkpoint kinase 2. Gut 2018;67:204-5. [PMID: 28476916 DOI: 10.1136/gutjnl-2017-314101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
702 Wang W, Zhang C, Yu Q, Zheng X, Yin C, Yan X, Liu G, Song Z. Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients. BMC Gastroenterol 2021;21:68. [PMID: 33579192 DOI: 10.1186/s12876-021-01638-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
703 Wan Y, Li M, Huang P. LINC01296 promotes proliferation, migration, and invasion of HCC cells by targeting miR-122-5P and modulating EMT activity. Onco Targets Ther 2019;12:2193-203. [PMID: 30988624 DOI: 10.2147/OTT.S197338] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
704 Aloia L. The influence of tissue spatial geometry and functional organisation on liver regeneration. Semin Cell Dev Biol 2021:S1084-9521(21)00246-9. [PMID: 34563460 DOI: 10.1016/j.semcdb.2021.09.011] [Reference Citation Analysis]
705 Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jang JW, Choi JY, Yoon SK, Yoo IR, Bae SH. 18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging. 2018;45:384-391. [PMID: 29124280 DOI: 10.1007/s00259-017-3871-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
706 Mima K, Kosumi K, Baba Y, Hamada T, Baba H, Ogino S. The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction. Hum Genet 2021;140:725-46. [PMID: 33180176 DOI: 10.1007/s00439-020-02235-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
707 Doganay L. Hepatocellular Cancer: Is Recurrence Inevitable? J Gastrointest Cancer 2017;48:274-5. [PMID: 28647821 DOI: 10.1007/s12029-017-9967-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
708 Guerra MT, Florentino RM, Franca A, Lima Filho AC, Dos Santos ML, Fonseca RC, Lemos FO, Fonseca MC, Kruglov E, Mennone A, Njei B, Gibson J, Guan F, Cheng YC, Ananthanarayanam M, Gu J, Jiang J, Zhao H, Lima CX, Vidigal PT, Oliveira AG, Nathanson MH, Leite MF. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut. 2019;68:1676-1687. [PMID: 31315892 DOI: 10.1136/gutjnl-2018-317811] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
709 Han T, Zhang Y, Yang X, Han L, Li H, Chen T, Zheng Z. miR-552 Regulates Liver Tumor-Initiating Cell Expansion and Sorafenib Resistance. Mol Ther Nucleic Acids 2020;19:1073-85. [PMID: 32044726 DOI: 10.10